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Abstract
This thesis describes some aspects of the immunobiology of the alphavirus Semliki 
Forest Virus (SFV) infection in the mouse. Both innate and adaptive immune responses 
are explored.
Chapter 2 describes experiments comparing the immune response to two strains of 
SFV, virulent and avirulent. Differences between these strains were identified in virus 
replication in spleen and brain, and their ability to induce IFN-a.
In chapter 3, lethality of vSFV was compared in B6 wild type mice and mice defective 
in exocytosis and or Fas-mediated pathways of cytolytic activity. Defective mice show 
more resistance than wild type B6 mice to the lethal vSFV infection. Absence of Tc- 
mediated cytolytic activity did not affect the outcome of vSFV infection, whereas NK 
cell-depletion delayed the mean time to death. This indicates a possible NK cell 
involvement in immunopathology.
In chapter 4, B6 wild type mice and vSFV-resistant mice (perfxgzmAB'/_, gld, Fas';', 
FasxgzmAB'7', and perf^xgld) were tested for changes in tissue virus titres. Reduced 
SFV replication was detected in perf!'xgld mice compared to all other mouse strains. In 
naive perf^xgld  mice, expanded population of activated macrophage and elevated 
expression levels of mRNA of IFN-y and TNF-a were detected. These factors may be 
responsible for the observed reduced virus titres.
In chapter 5, the cell surface expressions of activation markers CD69, CD86 and CD25 
on lymphocytes were investigated following vSFV and aSFV infections. A generalised 
and systemic elevation of CD69 and CD86, but not CD25, expression was detected at 
day 1 postinfection and returned to baseline by day 5 postinfection. This is also a 
feature of infections with other viruses, such as Adenovirus and Flavivirus. Using 
interferon receptor knockout mice, it could be concluded that this activation marker 
expression was mainly due to the action of IFN-I.
Vlll
In chapter 6, the consequences of the IFN-I mediated expression of activation markers 
on lymphocytes were investigated. The return to baseline levels of expression was due 
to down-regulation of cell surface expression than cell turnover via apoptosis. 
Following this down-regulation, a refractory period of about 9 days was required for a 
renewed cycle of activation markers to be expressed. Within that period, mice were 
more susceptible to secondary viral infections. Adoptive transfer of lymphocytes into 
new host facilitates activation markers re-expression in response to subsequent viral 
challenge. Therefore, it is possible that a refractory period is required to generate a 
second systemic IFN response following an acute viral infection.
Chapter 1: Background overview
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Chapter 1: Background overview
The immune system has evolved to protect the host from pathogenic infections. It has 
two main features: recognition and response. Based on these features, the immune 
response can be divided into an innate arm and adaptive arm. Pathogenic recognition by 
the innate arm is non-specific, based on non-clonally distributed receptors that 
recognize certain molecular patterns found in microbes but not in self-tissues. In 
addition, innate responses occur with same magnitude and kinetics irrespective of 
repeated encounters with any particular infectious agent. This part of the immune 
system involves a combination of molecular components such as complement and 
interferons (IFN), and cellular components such as macrophages, natural killer (NK) 
cells, and dendritic cells (DCs). These components may also play an important role in 
the induction of the more specific responses mediated by the adaptive arm of the 
immune system, which is, by contrast, based on pathogen-specific receptors expressed 
on cell surfaces of T and B lymphocytes. In addition, the adaptive immune response is 
characterized by a memory, enabling a more rapid and heightened immune reaction to a 
subsequent challenge by the same or a cross-reactive pathogen. B cells secrete 
immunoglobulins, the antigen reactive antibodies responsible for both eliminating 
extracellular microorganisms, and virus neutralization (the B cell response will not be 
further discussed). T cells, on the other hand, have two major roles in the adaptive 
immune response and are mediated by two subsets of T cells. T helper (or CD4+) cells 
play a regulatory role, which involves providing help to B cells (to make antibodies), 
and to CD8+T cells (to generate cytotoxic attack). CD8+, or cytotoxic, T (Tc) cells can 
eradicate intracellular pathogens by generating cytotoxic attacks, and or mediate host 
protection by the release of cytokines.
If a pathogen is able to breach barrier surfaces such as skin and mucous membranes, it 
will be faced by a concerted action of both the innate and adaptive arm of the immune 
system. In fact, the immune response to any given pathogen is one involving an 
overlapping action of both types. While providing the initial defense against any 
infectious agents, components of the innate’systems play important roles in shaping the 
more antigen specific adaptive response. For example, DCs at the immature stage are 
the major IFN producers during viral infection. In addition, DCs function as antigen 
presenting cells (APC) driving the adaptive response. IFNs, which limit viral 
replication, are one of the key factors required for DC maturation. At the same time, 
they act on lymphocytes by inducing the expression of costimulatory molecules and
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promote their activation and survival. In addition, NK cells can generate cytotoxic 
attacks against infected targets, similar to that generated by cytotoxic T cells after their 
DC-assisted activation.
1.1 Innate immunity
1.1.1 Interferons
Interferon is the term given to a family of inducible glycoproteins that are produced by 
cells in response to biological stimuli including viruses, bacteria, Mycoplasma, 
protozoa, cytokines, mitogens, natural and synthetic double-stranded RNA (ds-RNA) 
and other substances. IFN was discovered as an anti-viral agent in 1957 when Isaacs 
and Lindenmarf reported that influenza virus-infected chick cells produced a secreted 
factor that mediated a virus-resistant state active against both homologous and 
heterologous viruses (Isaacs and Lindenmann, 1957). This observation set the stage for 
subsequent studies that led to the elucidation of many aspects the IFN system. 
According to the cell types from which they were derived, three types of IFNs were 
originally recognised: leukocyte (a), fibroblast (ß), and immune (y) (Pestka et ah, 1987) 
(Samuel, 1991). The currently accepted classification divides IFNs, based on amino 
acid sequence homology, into two groups, type I (IFN-I) and type II (IFN-II). INF-I 
(IFN-a and IFN-ß) are induced by virus infection, whereas IFN-II (IFN-y) is induced by 
mitogenic or antigenic stimuli of lymphocytes (NK and T cells) (Samuel, 2001).
Type I IFN
The production of IFN-I is not confined to a specialised cells, and most cells of 
vertebrates are probably capable of producing IFN-I in response to viral infection 
(DeMaeyer and DeMaeyer-Guignard, 1998). Macrophages, NK cells, DCs, and 
fibroblasts were reported to produce IFN-I in response to viral infection or exposure to 
microbial pathogens (Belardelli and Gresser, 1996) (Celia et al., 1999a; Eloranta et al., 
1997; Rodel et al., 1998; Sing et al., 2000). However, by far the most potent producer 
of IFN-I are plasmacytoid DCs which can produce up to 10 fold higher IFN-I in vitro 
than any other cell type following microbial or viral challenge (Asselin-Paturel et al.,
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2001; Siegal et al., 1999). Other DCs can also act as a specialised IFN producer during 
certain viral infections (Diebold et al., 2003).
IFN-I are a diverse group of polypeptides that share a high degree of sequence 
homology (Kelley et al., 1983), and there are 2 families of IFN-I, IFN-a and IFNß, 
present in all mammalian species (Pestka et al., 1987). Both are inducible by viral 
infections and recognise the same multicomponent cell-surface receptor, the type I IFN 
receptor (IFN-IR) (Colamonici et al., 1992; Novick et al., 1994). The IFN-a family is a 
multigenic group of related polypeptides encoded by more than 13 genes in human and 
more than 10 genes in mice (Foster and Finter, 1998; Walter et al., 1998). IFN-ß, in 
contrast, exists as a single gene in most species, including human and mice.
Anti-viral effects
Viral infections are known to elicit an early induction of IFN-I synthesis that results in 
cellular resistance to viral infection, inhibition of viral replication, and impediment of 
viral dissemination (Sen and Ransohoff, 1993; van den Broek et al., 1995). Knockout 
mice lacking functional IFN-IR (IFN-IR'/_) are extremely susceptible to viral infections, 
such as vesicular stomatitis virus (VSV), Semliki Forest Virus (SFV), vaccinia virus 
(VACV), and Lymphocytic Choriomeningitis virus (LCMV) (Muller et al., 1994), 
Sindbis virus (SV) (Ryman et al., 2000), Venezuelan equine encephalitis virus (VEE) 
(White et al., 2001), and Murray Valley encephalitis (MVE) (Lobigs et al., 2003). High 
level of IFN-a/ß is an important feature of the early cytokine responses to viral 
infections. Ds-RNA, a known by product of many viral replication strategies, is a 
potent inducer of IFN-I (Biron, 1998; Malmgaard, 2004). The best-characterised direct 
anti-viral effect by IFN-I results from the production of two ds-RNA activated 
enzymes, (2’-5’)-oligoadenylate synthetase (2’5’OAS) and ds-RNA-dependent protein 
kinase (PKR). Production of these enzymes is dependent on JAK-STAT pathway 
activation by the interaction of IFN-a/ß with their specific cell surface receptor (IFN- 
IR) (reviewed in (Levy and Garcia-Sastre, 2001; Rebouillat and Hovanessian, 1999; 
Samuel, 2001). This direct effect of IFN-I results in protein synthesis inhibition in 
infected cells and thus limits the production of progeny viral particles (reviewed in 
(Jaramillo et al., 1995).
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Immunoregulatory effects
In addition to their anti-viral effect, IFN-I plays an important role in modulating both 
innate and adaptive immunity. The generation of activated T and B lymphocytes 
requires the recruitment and maturation of APCs. These APCs include B cells, 
monocyte/macrophages, and the most potent APC DCs. Immature (Plasmacytoid) DCs 
have been identified to be the major IFN-I producers (Asselin-Paturel et al., 2001; 
Siegal et al., 1999). IFN-I itself plays an important role in DCs maturation and survival 
(Luft et al., 1998). In vitro treatment of immature DCs with IFN-I induces phenotypic 
and functional maturation, as evident CD83, MHC-I and II, CD40, CD80, and CD86 
upregulation (Gallucci et al., 1999; Luft et al., 1998). This effect of IFN-I on DCs is 
mediated by only few other cytokines, such as interleukin-15 (IL-15) (Mattei et al., 
2001). Production of IL-15 itself is induced by IFN-I, and IL-15 activating effect on 
DC is reduced in the absence of IFN-IR (Mattei et al., 2001).
To successfully control a viral infection, virus-infected cells need to be eliminated prior 
to viral progeny formation and release. A successful anti-viral cell-mediated response 
depends on the ability of infected cells to present the viral antigens in conjunction with 
major histocompatibility complexes (MHC) molecules (Zinkemagel and Doherty, 
1974). IFN-I has the capacity to upregulate MHC protein expression, thereby 
promoting the anti-viral responses (Boehm et al., 1997). In addition, IFN-I induces 
proliferation of memory phenotype lymphocyte subsets and prolongs the survival of 
activated T cell populations. During viral infections, T cell proliferation, in particular, 
the CD44hl subset of CD8+T cell is induced by IFN-I (Tough et al., 1996), an effect 
mimicked by poly I:C, an inducer of IFN-I. In addition, in vitro treatment with IFN-I 
prevented the death of in vivo activated T cells without inducing their proliferation 
(Marrack et al., 1999). Therefore, IFN-I contributes to the large numbers of antigen 
specific and non-specific T cells that are induced during LCMV viral infection (Butz 
and Bevan, 1998; Murali-Krishna et al., 1998; Yang and Welsh, 1986).
The ability of IFN-I to induce maturation of DCs indicates their adjuvant activity. IFN-I 
regulates B cell functions such as Ab secretion and isotype switching (Stark et al., 
1998). Induction of isotype switching by IFN-I may be mediated by their effect on DCs 
(Le Bon et al., 2001) as well as their influence on T cell responses (Demeure et al., 
1994). Co-injection of IFN-I with a soluble protein antigen enhances in vivo T cell
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priming (Gallucci et al., 1999). IFN-I enhances T helper type 1 (Thl)-type responses by 
inhibiting the secretion of typical T helper type 2 (Th2)-type cytokines (interleukin 
(IL)-4 and IL-5) but promoting Thl-type cytokine production (IFN-y) in CD4+T cells 
(Brinkmann et al., 1993; Demeure et al., 1994). Such effect of IFN-I is also linked to 
isotype switching as the increased production of IFN-y subsequently promotes 
switching of B cells to synthesise IgG2a isotype antibodies (Sinigaglia et al., 1999). In 
addition, IFN-I promotes IgM, IgA, but not IgGl antibody production by B cells (Estes 
et al., 1998).
Moreover, IFN-I mediates activation of NK cell proliferation and cytotoxicity in vivo 
(Biron et al., 1999). However, IFN-I does not stimulate NK cell proliferation directly. 
They fail to elicit NK cell proliferation in vitro and exert anti-proliferative effects at 
high concentrations (Jewett and Bonavida, 1995). IFN-I influence on NK cell responses 
is dependent on secondary cytokines such as IL-15 (Waldmann and Tagaya, 1999). In 
addition, it has been shown that, during viral infections, IFN-I-mediated activation of 
NK cells is selective and does not extend to IFN-y expression (Nguyen et al., 2000). 
Furthermore, IFN-I may be crucial for anti-viral responses mediated by macrophages as 
it synergises with tumor necrosis factor (TNF) to induce inducible nitric oxide synthase 
(iNOS) and iNOS-dependent pathways of defences mediated by macrophage 
(MacMicking et al., 1997).
Type IIIFN
IFN-y (IFN-II) is a potent activator of the antimicrobial functions of phagocytes, and it 
has an essential role in resistance to many pathogenic bacteria, fungi and intracellular 
parasites (reviewed in (Trinchieri, 2003)). It is primarily an immunoregulatory cytokine 
(Landolfo et al., 1988), exclusively produced by cells of the immune system, most 
importantly antigen specific CD8+ T cells and CD4+ Thl cells during the adaptive 
phase of the immune response (reviewed in (Boehm et al., 1997; Lertmemongkolchai et 
al., 2001), but also NK and NKT cells during the innate phase (reviewed in (Biron, 
1999; Sen, 2001)). In addition, other cell types, for example macrophages, DCs, and 
y8T cells have also been reported to express IFN-y under certain conditions (Airoldi et 
al., 2000; Münder et al., 1998; Schindler et al., 2001; Stober et al., 2001).
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In contrast to the large number of IFN-I genes and proteins found in humans and mice, 
there is only one IFN-y gene and protein (Samuel, 2001). IFN-y exerts its effect through 
its species-specific cellular receptor, IFN-yR (or IFN-IIR) (Shtrichman and Samuel, 
2001). It plays an important role in both innate and adaptive immunity. A protective 
role for IFN-y has been demonstrated during several viral infections, including 
ectromelia virus (ECTV) (Karupiah et al., 1993), influenza A virus (Karupiah et al., 
1998), herpes simplex virus (HSV) (Cantin et al., 1999), hepatitis B virus (HBV) 
(Guidotti et al., 2000), and LCMV (Nansen et al., 1999). In addition, knockout mice 
lacking functional IFN-IIR are susceptible to some viral infections, notably VACV, and 
LCMV but not others such as VSV, and SFV (Muller et al., 1994). Most of the anti­
viral activity of IFN-y is related to its ability to activate macrophages and the resultant 
iNOS pathway (Guidotti and Chisari, 2000; Reiss and Komatsu, 1998). In addition, 
IFN-y can directly recruit and activate NK cells, and T cells to perform their effector 
functions (Guidotti and Chisari, 2000).
Furthermore, IFN-y upregulates the expression of MHC genes both class I (MHC-I) and 
class II (MHC-1I) and, thus, increases Ag-presentation during viral infection (Boehm et 
al., 1997; Rosa et al., 1983; Rosa et al., 1986) and/or makes cells more susceptible to 
cytolytic T cell lysis. This increases the efficiency of cellular immune responses against 
viral infections and several viruses, including cytomegalovirus (CMV) and varicella 
zoster virus (VZV), antagonise IFN-y-inducible MHC molecular expression (Abendroth 
et al., 2000; Miller et al., 1998).
1.1.2 Macrophages
Macrophages are long-lived phagocytic cells derived from bone-marrow monocytes, 
and circulate in the blood or reside in different organs and tissues (reviewed in 
(Guidotti and Chisari, 2000). Macrophages phagocytose foreign material as well as 
participating in the adaptive immune responses as an important APC for T lymphocytes 
(Gordon, 1998; Laskin and Pendino, 1995). In vitro studies indicated that macrophages 
are less efficient than dendritic cells, but more efficient than B cells in terms of antigen 
presentation (Kulkami et al., 1991). They discriminate between self and foreign
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antigens by expressing receptors for molecules not normally expressed on the cells of 
vertebrates, such as carbohydrates (Fraser et al., 1998). In addition, they express 
receptors for Ab (Fc-y receptors) and complement. Therefore, the coating of 
microorganism with Abs, complement, or both, enhances phagocytosis and enables Ag- 
specific Ab-dependent cellular cytotoxicity (Kurane et al., 1984; Macfarlan et al., 1977) 
reviewed in Aderem and Underhill* 1999).
Macrophages are a key component of the initial immune response against most 
pathogens, including bacteria and viruses (Blanden, 1982; Russell, 1995a). It is 
believed that macrophages are activated by virus infection or NK-, NKT- or T cell- 
derived cytokines. IFN-y is a very important priming factor required for macrophage 
activation, which must be accompanied by TNF to fully activate macrophages 
(reviewed in (Mosser, 2003). TNF, which functions as a second signal, can be secreted 
by macrophages themselves as a result of ligation of their toll-like receptors by 
microbial products such as LPS. In addition, many other cytokines, including IL-4, IL- 
12, M-CSF, GM-CSF, and TNF-a can activate macrophages (reviewed in (Guidotti and 
Chisari, 2000; Mosser, 2003)). Activated macrophages have been implicated in the 
infertility and autoimmunity in mice rendered genetically double deficient of both the 
Fas and exocytosis mediated pathways of cytotoxicity (see later) (Spielman et al., 
1998). Inactivating the expanded population of activated macrophages in these mice 
resulted in pancreas recovery and restored their fertility. Prostaglandin E can transform 
macrophages from activated into an inactivated state (Strassmann et al., 1994).
Once activated, macrophages synthesise cytokines (e.g. IFN-I, TNF-a) and NO, which 
have direct anti-viral activity, as well as other cytokines that have immunoregulatory 
functions (e.g. IL-1, IL-6, IL-8, IL-10, IL-12, IL-18, GM-CSF) (Dinarello, 1999; 
Laskin and Pendino, 1995). In vitro studies indicate that IL-1, TNF-a, and NO can 
inhibit the replication of HSV (Wildy et al., 1982), VACV (Keller et al., 1985), VSV 
(LeBlanc et al., 1990), and mouse hepatitis virus (MHV) (Keller et al., 1988). NO has 
also been shown to inhibit the replication of poliovirus, rhinovirus, MCMV, ECTV 
(reviewed in (Reiss and Komatsu, 1998), coxsackie virus (Saura et al., 1999), and HBV 
(Guidotti et al., 2000). Other macrophage-derived cytokines (e.g. IL-12) inhibit in vivo 
the replication of a number of viruses, including HBV (Cavanaugh et al., 1997), HSV 
(Carr et al., 1997), and encephalomyocarditis virus (Ozmen et al., 1995). Similarly, IL-
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18 treatment of mice controls VACV (Tanaka-Kataoka et ah, 1999) and HSV (Fujioka 
et ah, 1999) infections. Most of these anti-viral activities are secondary and probably 
due to the ability of IL-12 and IL-18 to induce IFN-y, since they do not display direct 
anti-viral properties by themselves.
1.1.3 Natural killer cells
Natural killer (NK) cells develop in bone marrow and mature cells are present in 
peripheral blood and spleen, with low numbers in lymph nodes (Biron and Brossay, 
2001). They migrate to inflamed tissues in response to different chemoattractants 
(Moretta et ah, 2002). These cells are a principal component of the innate immune 
responses to many infectious agents, including most viruses (reviewed in (Biron, 
1999)), and recently were identified to have a critical role in innate immune 
surveillance of tumors, particularly B cell lymphomas (Street et ah, 2004).
NK cell-effector function depends on a characteristic target-recognition system, which 
is based on the balance of inhibitory and activating signals delivered through a range of 
surface receptors (Cerwenka and Lanier, 2001b; Delves and Roitt, 2000). Killer cell 
immunoglobulin-like receptors (KIRs), lymphocytes antigen 49 complex (Ly49) 
receptors, and CD94/NKG2A receptors recognise major histocompatibility complex 
(MHC) class-I molecules and deliver inhibitory signals (reviewed in (Cerwenka and 
Lanier, 2001a). Activating signals can be delivered by a group of highly NK cell 
specific activating receptors, NKp30, NKp44, and NKp46, in addition to that of Ly49d, 
Ly49H, and NKG2D (Moretta et ah, 2001). The activating signal is usually overridden 
by the inhibitory signals dependent on recognising MHC-I molecules, expressed by all 
nucleated cells (Delves and Roitt, 2000). Thus, NK cells kill those target cells that have 
lost or express insufficient amount of MHC-I molecules, which occurs frequently in 
tumor and virus-infected cells (Moretta et ah, 2002). In addition to their receptors, NK 
cells in some mouse strains express cell surface phenotypic markers such as NK1.1 
(Koo et ah, 1984), and or DX5 (Ortaldo et ah, 1999). In addition, asialo ganglio-N- 
tetraosylceramide (asialo GM1) is expressed at high levels on NK cells of all vertebrate 
species (Trinchieri, 1989).
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NK cells can exert their effector function through generating cytotoxic attacks using 
either or both cytotoxic pathways: granule exocytosis and Fas-mediated pathways 
(Trapani and Smyth, 2002). These pathways are also used by cytotoxic T cells and will 
be discussed later. NK cell cytotoxicity can be induced by IFN-I, which is present at 
high and systemic levels during viral infection (Biron, 1999; Orange and Biron, 1996; 
Welsh, 1978b). Another effector function of NK cells involves the secretion of 
immunoregulatory cytokines such as IFN-y and TNF-a (Trinchieri, 1989). The role of 
NK cell-produced IFN-y in anti-viral defence may be related to inhibition of viral 
replication, induction of iNOS, and activating macrophages (reviewed in (Biron et al., 
1999), as discussed earlier.
In general, peak NK cell responses occur within the first several hours to days after 
primary infections, whereas adaptive T and B cell responses take more than a week to 
develop (Biron et al., 1999). Elevated NK cell-mediated cytotoxicity has been 
observed as a result of different viral infections including LCMV (Welsh, 1978a), SFV 
(Mullbacher and King, 1989), VACV (Karupiah et al., 1990), and others (reviewed in 
(Biron et al., 1999). In addition, the importance of NK cells in the anti-viral immune 
response was illustrated in many in vivo depletion studies. In vivo depletion of NK cells 
with antisera to asialo GM1 or monoclonal antibodies (MAbs) to NK1.1 resulted in 
enhanced MCMV growth in spleen, lung, and liver (Bukowski et al., 1983; Orange et 
al., 1995; Welsh et al., 1991; Welsh et al., 1994). A similar effect was also seen during 
infections with VACV and MHV, but not LCMV (Bukowski et al., 1983).
1.2 T cell immunity
T cells play a major role in adaptive immune responses. They express antigen-binding 
cell-surface receptors, T cell receptors (TCR), which have a certain amount of 
specificity and reactivity to their respective antigens (Ag). T cells recognize Ag in the 
context of MHC molecules on cell surfaces. There are two types of MHC molecules: 
MHC-I expressed by all nucleated cells of vertebrates, and MHC-II expressed only on a 
limited number of cell types in mouse on DC, macrophages, B cells and endothelial 
cells predominantly.
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T cells can be classified into two subpopulations, CD8+T and CD4+T cells, which 
provide different functions. CD8+T cells play a major role in eliminating intracellular 
pathogens by m ea^  of inducing apoptosis in their target cells following the 
recognition of foreign Ags in the context of MHC-I molecules. In contrast, CD4+T cells 
recognize Ag presented in the context of MHC-II molecules and play a coordinating 
role, helping both CD8+T and B cells. APC, such as DCs and macrophages, may 
represent the linking point between innate and adaptive responses, as they are important 
components of the innate and adaptive immune system.
1.2.1 MHC restriction
MHC molecules occupy a central stage in the generation of specific immune responses
as they form complexes with pathogen-derived Ag to be recognized by TCRs. Self Ags
are also presented by MHC molecules, but T cells with self Ag-reactive TCRs are
eliminated during the development of T cell repertoire, and will not be discussed here.
Ag presentation in the context of MHC molecules is an important requirement for T
cell activation and is called MHC-restriction (Zinkemagel and Doherty, 1974)
(Zinkemagel and Doherty, 1979; Zinkemagel et al., 1976). It involves both classes of
MHC molecules: class I and class II. MHC-I (H-2K, D, and L in mouse, HLA-A, B,
and C in humans) molecules present Ags of principally endogenous origin to be
recognized by CD8+T cells. In addition, MHC-I molecules function as a ‘self-marker’
(Ljunggren and Karre, 1990) recognized by inhibitory NK cell receptors (Brennan et
al., 1996). In contrast, MHC-II (I-A and I-E in mouse, HLA-DP, DQ, and DR in
«
humans) molecules present Ags of predominantly exogenous source to be recognized 
only by CD4+T cells.
MHC-I and the presentation of endogenous Ag
MHC-I molecules are expressed on the surfaces of almost all nucleated cells (Hood ct 
al., 1983; Steinmetz et al., 1982), and each molecule consists of a heavy chain and a 
light chain (reviewed in (Jones, 1997)). The heavy chain, called the a-chain, is a 
transmembrane glycoprotein consisting of cytoplasmic tail, transmembrane region, and 
extracellular region (reviewed in (Jones, 1997; Klein and Sato, 2000). The a-chain is 
non-covalently linked to a soluble protein known as ß2-microglobulin (ß2M) that forms 
the light chain (Jones, 1997). Crystallographic studies have revealed that the
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extracellular portion of the a-chain consists of three domains; a l, a2, and a3 (Bjorkman 
et al., 1987b; Stem and Wiley, 1994). On the distal surface of MHC-I molecules, al 
and a2 domains form the binding groove for the antigenic peptide (Bjorkman et al., 
1987a). ß2M associates with the a3 domain and supports the membrane-distal al and 
a2 domains, resulting in minimal contact between a l, a2 and a3 domains. CD8 
molecules, the cell marker for CD8 T cells, are responsible for the exclusive 
recognition of MHC-I molecules. CD8 molecules bind to a3 domain and contact ß2M 
without causing conformational changes in the peptide-binding site (Gao et al., 1997). 
MHC-I molecules are assembled in the endoplasmic reticulum (ER), and ß2M proteins 
appear to be crucial for their cell surface stability (reviewed in (Jones, 1997)). Surface 
expression of MHC-I heavy chains in cell lines lacking ß2M is minimal, and nascent 
MHC-I a chains accumulate in the ER (Arce-Gomez et al., 1978; Ploegh et al., 1979).
'V?,
Mice lack ß2M expression as a result of gene knockout do not express any detectable 
MHC-I molecules and have no mature CD8+ T cells (Zijlstra et al., 1990).
MHC-I molecules are loaded with peptides in the ER before being exported via the 
Golgi apparatus to the cell surface (Klein and Sato, 2000). Self proteins in the cytosol 
are degraded into peptides by proteasomes (Heemels and Ploegh, 1995; Khan et al., 
2001; Reits et al., 2000; Schubert et al., 2000; Yewdell, 2002). Since viruses replicate 
within infected cells, viral mRNAs are transcribed into proteins in the cytosol, and 
some viral proteins are degraded in the proteasomes (Klein and Sato, 2000). These 
peptides generated in the cytosol are transported into the ER by the transporter 
associated with antigen processing (TAP), which is a member of the ABC-transporter 
family (Androlewicz et al., 1993; Neeljes et al., 1993; Shepherd et al., 1993). The 
optimal length of peptide transported by TAP in human and mice is similar, being 8-13 
amino acids (Cresswell et al., 1994; Momburg et al., 1994). Antigenic peptides 
transported into the ER by TAP are loaded onto newly synthesized MHC-I molecules. 
This process is tightly regulated by ER-resident chaperones, such as calnexin, 
calreticulin, tapasin, and ERP57 (reviewed in (Antoniou et al., 2003; Pamer and 
Cresswell, 1998). These peptide-loaded MHC-I molecules are transported from the ER 
to the cell surface through the Golgi apparatus (Spiliotis et al., 2000).
Interestingly, some APCs have the ability to present exogenous antigen by MHC-I to 
prime CD8+T cells, in addition to their ability of presenting exogenous antigen by
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MHC-II molecules to CD4+T cells (Kovacsovics-Bankowski et al., 1993; Sigal et ah, 
1999); (Norbury et ah, 1995) (Albert et ah, 1998; Norbury et ah, 1997). This 
phenomenon is called ‘cross-priming’ (Bevan, 1976a; Bevan, 1976b).
MHC-II and the presentation of exogenous Ag
MHC-II molecules are expressed mainly on the surface of professional APCs, which 
include DCs, macrophages, and B cells, and on endothelial cells exposed to IFN-y 
(reviewed in (Hansen and Sachs, 1989); and (Robinson and Kindt, 1989)). Antigen 
presentation by MHC-II molecules depends on endocytosis (or phagocytosis) of 
extracellular proteins into endosomes by APCs.
Although the overall structure of MHC-II molecules is similar to that of MHC-I
molecules featuring a peptide-binding groove, they are of heterodimers formed by
association of two chains a and ß (Stem and Wiley, 1994). Each chain consists of two
extracellular domains, transmembrane region, and a cytoplasmic tail. The membrane
distal domain of each chain, al and ßl domains, form the peptide-binding groove
(Klein and Sato, 2000). This peptide-binding groove binds longer peptides compared to
MHC-I molecules (Hunt et ah, 1992). MHC-II molecules assemble in the ER with a
third transmembrane protein, the invariant chain (Ii) (Bakke and Dobberstein, 1990).
The complex of MHC-II and Ii leaves the ER by way of the Golgi apparatus into
primary lysosomes, which fuse with the endosomes to form peptide-loading
compartments (reviewed in (Bakke and Dobberstein, 1990; Klein and Sato, 2000;
Lotteau et ah, 1990; Pieters et ah, 1993). Enzymes brought into this compartment by
&
lysosomes degrade the engulf proteins and the bulk of the Ii. This process leaves behind 
a small fragment, CLIP (MHC-II- associated invariant chain peptide), within the 
peptide-binding groove of the aß heterodimer (reviewed in (Turk et ah, 2001). 
Antigenic peptides are loaded into MHC-II molecules with the help of HLA-DA 
molecules, which are class Il-like heterodimeric proteins synthesised in the ER (Kelly 
et ah, 1991; Roche, 1995). Ag-loaded MHC-II molecules are exported and expressed 
on the cell surface where they can be recognized by CD4+T cells (Klein and Sato, 
2000).
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1.2.2 T cell receptors
TCRs control key events in the life of T cells including their development in the 
thymus, and their differentiation into effector populations. TCR consists of 
heterodimers of polypeptide chains of either a-ß or y-8. A small population of T cells, 
which is not discussed here, express yöTCR (de Wolf-Peeters and Achten, 2000), 
whereas the majority of T cells express aßTCR. The TCR complex is usually 
assembled in the ER and contains a single TCRaß heterodimer and three signaling 
dimers, CD35s, CD3ye and ££. The TCR heterodimer is responsible for Ag binding, 
whereas intracellular signal transduction is initiated by signaling dimers (reviewed in 
(Call and Wucherpfennig, 2004)).
The T cell response to a particular Ag is affected by TCR affinity to that particular Ag, 
the number TCRs engaged, and the duration of TCR engagement (Constant and 
Bottomly, 1997; Germain and Stefanova, 1999; Labrecque et al., 2001; Lyons et al., 
1996; McKeithan, 1995). Using a transgenic mouse model to study CD4+T cell 
differentiation into Thl and Th2, Rogers and Croft have shown that both affinity and 
duration of binding to APC determines the pattern of cytokines secreted by Th cells 
(Rogers and Croft, 1999). Differentiation of CD4+T cells towards a Th2 pattern of 
cytokine expression resulted from moderate stimulation, while a very high level of 
stimulation induces differentiation into cells expressing the Thl cytokines (Rogers and 
Croft, 1999). In short-term experiments, however, the Thl differentiation required 
lower levels of stimulation than the Th2 one, and it is still unclear how different signal 
strengths generated from different TCR binding affinities to different Ags are processed 
by naive CD4+T lymphocytes to derive the two differentiation pathways in the 
periphery. In contrast, TCR binding affinity in thymic selection of T cells is relatively 
well understood (reviewed in (Ashton-Rickardt and Tonegawa, 1994; Miller and 
Basten, 1996; von Boehmer et al., 2003). Immature T cells (CD4'CD8') migrate from 
the bone marrow to the thymus where they begin to express CD4 and CD8 molecules 
and rearrange their TCR a and ß genes (Lo, 1992; Mondino et al., 1996). These CD4 
and CD8 molecules together with TCR heterodimers are used in both positive and 
negative intra-thymic selection. Cells that fail to recognize self-peptide-MHC molecule 
complexes will be eliminated during the positive selection process. The positively 
selected cells contain cells with high reactivity to self peptide-MHC complexes; these 
cells are eliminated in a negative selection process. The result of both positive and
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negative selection is the large peripheral repertoire of T cells that can recognize MHC 
molecules bound to virtually any possible foreign peptide but tolerate self peptide- 
MHC complexes.
1.2.3 T cell populations
T cells are pivotal in the immune system, exerting effector function to eliminate 
pathogens and contribute to immunoregulation. Peripheral T lymphocytes can be 
separated on the bases of their expression of the cell-surface marker CD4 and CD8 
(Macphail and Stutman, 1987; Matsubayashi et al., 1989). T cell activation is restricted 
by their ability to recognise Ags bound to MHC molecules with the CD4+ subset, or Th 
cells, recognises Ags bound to MHC-II molecules, whereas the CD8+ subset, or Tc 
cells, recognises Ags presented by MHC-I molecules. Some CD4+T cells, however, can 
mediate killing activity (Kaplan et al., 1984), and some CD8+Tcells do secret cytokine 
to mediate regular activity on other immune cells (Callan et al., 2000). Therefore, the 
classification of CD4+T cells as helper and CD8+T cells as Tc is not absolute.
CD4+T cells
CD4+T cells are primarily responsible for co-ordinating the immune response through 
direct interaction with other cells and by secreting cytokines. They collaborate with B 
cells in the generation of effective humoral immunity as they induce antibody isotype 
switching and enhance antibody production. In addition, they play an important role in 
the induction of the cellular immune response by providing help for CD8+T cell 
activation. Generally, based on cytokine secretion patterns, Th cells can be divided into 
two subsets; Thl and Th2. Thl cells secrete IL-2, TNF-a, and IFN-y, while Th2 cells 
secrete IL-4, IL-5, IL-10, and IL-13 (reviewed in (Del Prete, 1998; Mosmann and 
Coffman, 1989)). T cells expressing both Thl and Th2 cytokines have also been 
described in some studies and designated as ThO cells (Maggi et al., 1988; Paliard et al., 
1988). These cells mediate intermediate effects, depending on the ratio of cytokine 
produced and the nature of the responding cells, and they probably represent a 
heterogenous population of partially differentiated effector cells consisting of multiple 
discrete subsets.
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Thl and Th2 responses are antagonistic to each other and one subtype is usually 
dominant in a response to any particular pathogen in any one circumstance. Most 
intracellular pathogens, including viruses, intracellular bacteria, protozoa, and fungi, 
induce Thl responses which regulate the cellular immune response. On the other hand, 
most extracellular pathogens induce Th2 responses that enhance humoral responses. 
Th2 cells are also predominant in allergic diseases (Parronchi et al., 1991). Both 
subtypes are defined as populations of cells, since it has been demonstrated that most of 
these cells secrete only one cytokine per cell at any one time (Karulin et ah, 2000). The 
differentiation of T cell precursors’ into Thl and Th2 may depend on cytokine 
environment, Ag presentation site, physical form and dose of Ag, and type of adjuvant 
(reviewed in (Del Prete, 1998)). IFN-I is a crucial factor during viral infection that 
induces Thl differentiation leading to Tc cell responses as illustrated by the absence of 
Tc cell responses during LCMV infection in IFN-IR knockout mice (Muller et ah, 
1994).
CD4+T cells play an important role in anti-viral responses as both Thl-derived 
cytokines, such as TNF-a and IFN-y, and Th cell-dependent anti-viral Abs have been 
shown to be important in the control of some viral infections, such as influenza virus 
(Eichelberger et ah, 1991; Graham et ah, 1994; Scherle et ah, 1992), VSV (Maloy et 
ah, 2000), and VACV (Kagi et ah, 1995b; Spriggs et ah, 1992). The importance of Th 
cells in the induction of the anti-viral Tc cell response varies with different viruses as 
absence of Th cells significantly reduces the Tc cell response to LCMV, VSV, ECTV, 
and VACV ((Battegay et ah, 1996; Leist et ah, 1989), whereas deficiency of Th cells 
does not cause impairment of the Tc cell response to Sendai virus (Hou et ah, 1995). In 
addition, cytolytic CD4+T cells can be generated using different experimental protocols 
(reviewed in (Kagi et ah, 1996)). Their MHC-II-restricted killing activities appear to be 
mainly mediated by the Fas-dependent pathway. Cytolytic CD4+T clones have been 
established from peripheral blood monocytes of individuals during Dengue virus 
infection (Kurane, L, et ah, 1995 and 1998), or following immunisation with JE vaccine 
(Mullbacher et ah, 2003).
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CD8+T cells
Tc lymphocytes express CD8 molecules and recognise Ag presented by MHC-I 
molecules. They have been implicated as critical effector cells during viral infections 
(Blanden, 1974; Reddehase et al., 1987; Yap and Ada, 1978). Their anti-viral activity is 
attributed to their ability of generating cytotoxic attack against virus-infected cells, in 
addition to their ability of secreting cytokines (reviewed in (Mullbacher, 2003)). CD8+T 
cells can secrete cytokines such as, IFN-y and TNF-a, as well as chemokine which, in 
addition to their anti-viral effect, function to recruit and/or activate the microbicidal 
activities of effector cells such as macrophages and neutrophils (reviewed in (Harty and 
Bevan, 1999)). In addition, their cytokine profile appear/similar to that described for 
CD4+T cells and they can also be subdivided into two subsets, Tel and Tc2 (reviewed 
in (Karupiah, 1998)). The most investigated CD8+T cells effector function, however, is 
their ability to generate cytotoxic attack, which requires direct contact with their 
targets. Activated Tc cells are able to induce cytolysis of target cells by two distinct 
molecular pathways ((Berke, 1995; Kagi et al., 1994a; Lowin et al., 1994): the granule 
exocytosis and the Fas-mediated pathways. These two pathways also mediate target cell 
killing by NK cells.
Granule exocytosis
Granule exocytosis is arguably the principal cytolytic pathway used by Tc cells to 
eliminate virus-infected cells. Granules of activated Tc cells contain various proteins, 
including a membrane-disrupting protein named perforin (perf), and a number of 
structurally related serine proteases known.as granzymes (gzm) (reviwed in (Trapani 
and Smyth, 2002). Generation of lytic granules is an important process in the 
differentiation of T cells into cytolytic effector cells. Upon Ag encounter, the effector 
cell secretes the granule contents into the space between target and effector cell, in a 
Ca2+-dependent process that is associated with extensive cytoskeleton reorganisation 
(reviewed in (Griffiths, 1995)). The role of granule exocytosis in the immune response 
during viral infections has been extensively investigated using mice carrying targeted 
null mutations in key elements of the cytolytic machinery, including perf, gzmA and B 
(Kagi et al., 1999; Matloubian et al., 1999; Mullbacher et al., 1996; Mullbacher et al., 
1999a; Mullbacher et al., 1999b; Ramshaw et al., 1997; Simon et al., 1997).
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Perf plays a pivotal role in granule-mediated cytotoxicity with Tc cells and NK cells 
from perf-deficient (perf7') mice being defective in their ability to induce both 
membrane damage and apoptosis in vitro (Kagi et al., 1994a; Kojima et ah, 1994); 
(Lowin et ah, 1994). Perf is usually released as monomers which polymerise in the 
plasma membranes of target cells, forming pores (Liu et ah, 1995). This action of perf 
has considerable analogy to the complement component C9 (Shinkai et ah, 1988; 
Young et ah, 1986), and can cause osmotic damage of target cells (Lichtenheld et ah, 
1988; Shinkai et ah, 1988). However, apoptotic death rather than osmotic damage is 
considered to be the main feature of target cell death, and is characterised by chromatin 
condensation, extensive membrane blebbing, and DNA fragmentation (Shi et ah, 
1992a; Shi et ah, 1992b). This is explained by the synergistic action of perf with other 
lytic granule constituents, gzms.
Gzms are lymphocyte granule serine proteases belonging to the trypsin family (Odake 
et ah, 1991), located in cytoplasmic granules of Tc and NK cells (Pasternack et ah, 
1986), and released directly into the immunological synapse between the effector and 
the target cell (Stinchcombe et ah, 2001). A total of 11 highly homologous (with 38- 
67% homology to gzmB) gzms have been found in human and rodent cytolytic cells 
(Haddad et ah, 1991), and they contain the catalytic triad (His-57, Asp-102, and Ser- 
195) of the trypsin family serine proteases (Kam et ah, 2000). Although gzms can 
diffuse through pores formed by perf, they can also enter the cytoplasm of target cells 
independently of perf, either via receptor-mediated endocytosis or through 
macropinocytosis (reviewed in(Trapani and Smyth, 2002)). The two most studied gzms 
are gzmA and B. The participation of gzmA (Beresford et ah, 2001; Fan et ah, 2002) 
(Fan et ah, 2003a; Fan et ah, 2003b; Pinkoski and Green, 2003) and gzmB (Metkar et 
ah, 2003; Pardo et ah, 2002; Sharif-Askari et ah, 2001; Smyth and Trapani, 1995; 
Sutton et ah, 2000; Trapani and Smyth, 1993; Yang et ah, 1998) in cytotoxic cell- 
mediated killing have been investigated extensively. GzmB triggers an endogenous cell 
death cascade by activating key pro-apoptotic target cell caspases ((Daniels et ah, 1999; 
Fernandes-Alnemri et ah, 1996; Song et ah, 1996; Srinivasula et ah, 1996). Studies 
using gzmB-deficient (gzmB'7') mice have illustrated its crucial role for rapid induction 
of apoptosis (Heusel et ah, 1994). GzmA, a tryptic protease, has been shown to act 
through a distinct pathway, characterised by delayed kinetics of apoptosis induction 
(Beresford et ah, 1999; Beresford et ah, 2001; Shi et ah, 1992a; Shresta et ah, 1999).
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Mice deficient in both gzmA and B (gzmAB7') are severely defective in both early and 
late DNA fragmentation (Shresta et ah, 1999; Simon et ah, 1997). In addition, the 
presence of gzmA enhances significantly DNA fragmentation by gzmB (Beresford et 
ah, 1999; Nakajima et ah, 1995). This synergistic effect has been illustrated by the 
increasing susceptibility to ECTV infection in gzmA'7', gzmB7', and gzmAB7' mice 
(Mullbacher et ah, 1999b). Furthermore, the ability of cytotoxic cells from gzmB7' 
mice to induce rapid target-cell DNA fragmentation is markedly reduced (Heusel et ah, 
1994; Shresta et ah, 1995). In contrast, cytotoxic cells from gzmA7" mice have normal 
cytotoxic responses in vitro (Ebnet et ah, 1995; Shresta et ah, 1997), but these mice can 
no longer restrict the spread of HSV in neurons (Pereira et ah, 2000), and are unable to 
clear ECTV (Mullbacher et ah, 1996). Interestingly, perf and/or gzms appear to 
contribute to the mortality and morbidity during MVE virus infection in mice (Licon 
Luna et ah, 2002). Similarly, the granule exocytosis pathway was reported to contribute 
to virus infection-induced autoimmune diseases such as coxsackie virus-induced 
myocarditis (Gebhard et ah, 1998) and HSV-1-induced keratitis (Chang et ah, 2000).
Fas pathway
Tc cells can also generate cytotoxic attack by up-regulating their surface expression of 
Fas ligand (Fas.L) (also known as CD178). Engagement of the target cell death 
receptors Fas (also termed APO-1 or CD95) by Fas.L expressed on effector Tc cells 
results in classical caspase-dependent apoptosis (Itoh et ah, 1991; Lowin et ah, 1994; 
Nagata and Golstein, 1995; Rouvier et ah, 1993; Stalder et ah, 1994). Fas.L has been 
shown to be homologous to membrane TNF (Suda et ah, 1993), and can be rapidly 
expressed on CD8+ and CD4+T cells following TCR engagement (Carter and Dutton, 
1995; Ramsdell et ah, 1994; Suda et ah, 1995). This Fas.L induction appears to involve 
the activation of src-family and other tyrosine kinases, which requires RNA and protein 
synthesis and the presence of calcium, and is inhibited by cyclosporine A (Anel et ah, 
1994; Anel et ah, 1995).
Fas belongs to the TNF receptor family, and possesses structural similarity with TNF 
receptor-1, a conserved extracellular region and a cytoplasmic domain essential for the 
induction of apoptosis (check ref (Nagata and Golstein, 1995; Tartaglia et ah, 1993). 
Fas is constitutively expressed in the thymus (Watanabe-Fukunaga et ah, 1992), in all 
murine (Andjelic et ah, 1994; Drappa et ah, 1993; Nishimura et ah, 1995) and human
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(Debatin et al., 1994) thymocyte subsets. In the periphery, Fas expression can be 
induced by activation on both T and B cells (Watanabe-Fukunaga et al., 1992) 
(Watanabe et al., 1995). Induction of Fas expression upon TCR triggering requires the 
product of the TDAG51 gene (Park et al., 1996). Fas expression on T cells occurs at a 
late stage of activation (2-3 days) (Miyawaki et al., 1992), rendering them susceptible 
to activation-induced cell death (AICD), which has been shown to be Fas-dependent 
(Alderson et al., 1995; Dhein et al., 1995; Ju et al., 1994; Sytwu et al., 1996; Zheng et 
al., 1995). Outside the immune system, Fas is constitutively expressed in several organs 
such as the liver (Watanabe-Fukunaga et al., 1992).
The Fas pathway is similar to granule exocytosis pathway in that maximal expression 
of the Fas.L requires an initial activation signal by the TCR (Zheng et al., 1998). The 
Fas pathway is believed to be associated with immune regulation, particularly in 
immune system homeostasis (Alderson et al., 1995; Ju et al., 1995; Nagata and 
Golstein, 1995; Rathmell et al., 1995; Rouvier et al., 1993; Russell, 1995b)). Mice with 
a loss-of-function mutation in the Fas gene (Ipr), and Fas.L gene (gld) suffer from 
progressive expansion of peripheral lymphoid populations, resulting in massive 
lymphadenopathy, splenomegaly and lymphocyte infiltration in organ such as liver and 
kidney (Watanabe-Fukunaga et al., 1992) (reviewed in (Nagata, 1999)). The Ipr, which 
is an insertion of transposon into intron 2 of Fas gene, does allow the expression of 
minute amounts of functional protein (Chu et al., 1993). In contrast, gld, which is a 
point mutation in the extracellular region of Fas.L that affects the binding to Fas, has 
been considered a null allele (Takahashi et al., 1994). In addition, Fas.L-knockout 
(Fas.L'7') (Karray et al., 2004), and Fas-knockout (Fas'7') (Adachi et al., 1995) mice 
suffer similar lymphadenopathy and splenomegaly to that seen in Ipr and gld mice. This 
may be related to the role of the Fas pathway in AICD, which serves to down-regulate 
the expansion of activated T cell clones following their response to Ags (Waring and 
Mullbacher, 1999).
It was generally believed that the granule exocytosis pathway is the primary mechanism 
for the elimination of intracellular pathogens including viruses, whereas the Fas 
pathway of cytotoxicity plays an immunoregulatory role (Kagi et al., 1995a; Nagata, 
1997; Rouvier et al., 1993). Recent evidence, however, suggests that in many virus 
infections both pathways are operative as mice defective in either cytolytic pathway
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show delayed and reduced mortality when infected with MVE (Licon Luna et al., 
2002), and the concerted action of both pathways is mandatory for the development of 
LCMV infection-induced hepatitis (Balkow et ah, 2001). In addition, Tc cells from 
perfA mice can lyse their target cells via Fas-Fas.L interaction (Simon et ah, 2000). In 
addition, Ag-dependent release of IFN-y by perf-deficient Tc cells increases the 
expression of Fas on target cells facilitating their killing in Fas/Fas.L-dependent 
pathway (Mullbacher et ah, 2002). Therefore, both cytotoxic pathways are operative 
during viral infections. Fas-mediated apoptosis, and not granule exocytosis-mediated 
apoptosis, is implicated in MHC-I-restricted killing of neurons by virus immune CD8+T 
cells (Medana et ah, 2000). This is supported by the ability of Fas.L to protect neurons 
against granule exocytosis-mediated killing (Medana et ah, 2001). This finding 
suggests that cytolytic effector cells, such as NK and Tc cells, may use only the 
Fas/Fas.L pathway to eliminate neurons infected with neurovirulent viruses.
1.2.4 T lymphocyte activation
Given the ability of Tc cells to generate tissue destruction, their activation must be 
tightly regulated. Naive Tc cell precursors have no effector function and must undergo 
an activation process requiring 1-3 days for maximal activity. This activation process 
requires Ag recognition mediated by the TCR. However, signalling through TCR alone 
is not sufficient by itself to initiate the maturation pathway of naive T cells. A second, 
costimulatory signal delivered to T cell, simultaneous with TCR ligation, is required. 
This concept of two signals required for lymphocytes activation was originally 
developed for B cells (Bretscher and Cohn, 1970), before it was adapted for T cells 
(Lafferty and Cunningham, 1975). Cells providing the costimulatory signals required 
for naive T cells priming are rare. Only so-called professional APC, like B cells, 
macrophages and dendritic cells, have the ability to present Ag and provide 
costimulatory signals. Once activated, T cells do not need costimulatory signals to 
generate their effector functions whether this be cytotoxicity or cytokine production. 
Importantly, the same signals that activate T cells also stimulate their proliferation, and 
virus immune T cells can expand several orders of magnitude in response to viral 
infections (reviewed by (Doherty and Christensen, 2000)).
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Costimulatory molecules
Upon Ag uptake, APC upregulate several membrane-associated accessory molecules 
important for T cell priming. Both CD80 (also known as B7.1) and CD86 (also known 
as B7.2) are expressed predominantly on APC. CD86 has been implicated as the 
predominant costimulatory ligand during initial Ag encounter (Lenschow et al., 1993), 
whereas CD80 plays a role in modulating the strength of the ongoing immune response 
(Hathcock et ah, 1994; Lenschow et ah, 1994; Miller et ah, 1995). Early studies 
indicated that CD80 and CD86 influence Th cell phenotype differentiation with CD80 
promoting the Thl phenotype and CD86 the Th2 phenotype (Kuchroo et ah, 1995; 
Lenschow et ah, 1995), but this is still controversial (MacPhee et ah, 2001). Both CD80 
and CD86 can bind and induce signals through CD28, which is constitutively expressed 
on T cells and appears to be the most important costimulatory molecule (Green et ah, 
1994; Vesosky and Hurwitz, 2003). Ligation of CD28 enhances T cell/APC interaction 
and facilitates TCP. engagement and signalling (Michel et ah, 2001). The effects of 
CD28 ligation include, an increase in IL-2 production, upregulation of CD25 (the IL-2 
receptor) expression (Jenkins et ah, 1991; Martin et ah, 1986), as well as upregulation 
of anti-apoptotic molecules like Bcl-xL, protecting from AICD (Boise et ah, 1995). 
CD 152 (also known as CTLA-4), which is upregulated following T cell activation, can 
also bind to CD80 and CD86. CD 152 binding to CD80 or CD86, however, has an 
inhibitory effect on T cell activation (Krummel and Allison, 1995; Krummel and 
Allison, 1996). In addition, CD 154 has much higher binding affinity for CD80 and 
CD86 compared to CD28 (Linsley et ah, 1994). Mice deficient in CD 152 suffer from 
lymphoproliferative disorder and die within 4 weeks of birth (Waterhouse et ah, 1995). 
In vitro study, investigating the costimulatory effect of CD 152 on Th cell 
differentiation, showed that CD 152 engagement promotes Thl differentiation, probably 
by inhibiting IL-4 secretion (Kato and Nariuchi, 2000).
Other costimulatory molecules include ICOS and PD-1, members of the CD28 family 
of molecules (reviewed in (Sharpe and Freeman, 2002)). Beside the CD28 family, 
molecules such as LFA-1, 4-1BB, 0X40, CD40, CD2 and others do provide adhesion 
and costimulatory effects (reviewed in (Vesosky and Hurwitz, 2003; Watts and 
DeBenedette, 1999)). Among these different molecules, CD69 has been used as an 
activation marker. Many different cell types including T, B, NK cells, and monocytes
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express CD69, which is a member of the NK cell gene complex family of signal 
transducing receptors (Marzio et al., 1997). In addition, CD69 is one of the earliest 
induced cell-surface Ag expressed by T cells following activation, and may play a role 
in their differentiation (reviewed in (Ziegler et ah, 1994)). CD69, CD86 and CD25 
expression levels on B and T cells have been used as an indication for their activation 
(Braun et ah, 2002; Hakamada-Taguchi et ah, 1998; Lowenthal et ah, 1985; Tough et 
ah, 1996).
Ag presenting cells
APC can uptake exogenous protein, via phagocytosis or receptor-mediated endocytosis, 
and present it in the context of MHC-II molecules. As they express costimulatory 
molecules, they have the ability to activate naive T cells. Among them, DCs are the 
most efficient APCs (Bhardwaj et ah, 1992; Bhardwaj et ah, 1993; Croft et ah, 1992; 
Macatonia et ah, 1995; Steinman and Witmer, 1978; Van Voorhis et ah, 1983). The 
frequency of naive antigen reactive T cell-clones is low to any given MHC-II/peptide T 
cell determinant (Banchereau and Steinman, 1998), and less than 1% of the total T cell 
pool even at the hight of the immune response to a viral infection (Tough and Sprent, 
1994; Tripp et ah, 1995). Infected cells normally lack the costimulatory molecules 
required for the clonal expansion or proliferation of T cells, cytokine production, and 
effector cells development. DCs provide the bridge between Ag-presentation as well as 
providing costimulation required for T cell activation. DCs are present in most tissues 
to capture and present Ag, after which they upregulate the expression of costimulatory 
molecules, and migrate to lymphoid tissues (reviewed in (Banchereau and Steinman, 
1998; Carbone and Heath, 2003)). Therefore, naive T cells survey the entire body for 
their reactive Ag by migrating through secondary lymphoid tissues screening Ag 
presented by DC.
Considering the intracellular parasitic nature of viruses and their dependence on host 
protein synthesis machinery for replication, all viral proteins are potentially accessible 
to the endogenous MHC-I presentation pathway and to surveillance by CD8+T cells 
(Harty et ah, 2000). Therefore, activation of CD8+T cells during viral infection requires 
the infection of APC, or DC, but not all viruses do infect DCs. A process called cross-
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priming (Bevan, 1976a; Bevan, 1976b), or cross-presentation (reviewed in (Heath and 
Carbone, 2001)) overcomes the requirement of DCs infection in order to activate 
CD8+T cells. Bone-marrow-derived host APC, particularly DCs can efficiently take up 
material from apoptotic cells and present antigens derived from this material on MHC-I 
(den Haan et al., 2000). Relatively small molecules (3-20KD) have been demonstrated 
to be able to escape the endocytic system of DCs into the cytoplasm where they gain 
access to cytosolic antigen-processing machinery (MHC-I Ag presenting pathway) 
(Rodriguez et ah, 1999). Recently, Bevan has suggested that DCs can present Ag via 
MHC-I in the absence of CD4+T cell help, if there is a danger signal in the form of 
inflammatory cytokines (Bevan, 2004). In the absence of an inflammatory signal, a 
signal from CD4+T cells to DCs is crucial to induce MHC-I Ag presentation for CD8+T 
cell priming. In addition, ligation of CD40 via CD40L on activated CD4+T cells may 
play an important role in DCs activation (Ludewig et ah, 1995) and stimulate secretion 
of IL-12, an inducer of Thl responses (Macatonia et ah, 1995). These CD40-associated 
features indicate that DCs may be the crucial link that provides CD4+T cell help for 
CD8+T cell activation, (reviewed in (Bevan, 2004)).
Mouse DCs consist of a large number of subpopulations which can be identified 
according to their cell surface expression of CD8a, CD4, CD lib, Gr-1 and B220 
(reviewed in (Carbone and Heath, 2003; Shortman and Liu, 2002)). Classification on 
the basis of CD4 and CD8a expression suggested at least 3 distinct subpopulations of 
DCs namely CD4+, CD4'CD8' (DN), and CD8+ (Shortman and Liu, 2002). Despite the 
controversy as to whether these populations constitute stable DC subsets or 
differentiation stages, it is thought that these subsets vary in their cytokine production 
potential, and, possibly, in their function. It has been argued that CD8+a DC are 
uniquely able to synthesise IL-12 and promote Thl responses while other subsets fail to 
make IL-12 and promote Th2-dominated immunity (Maldonado-Lopez et al., 1999; 
Pulendran et al., 1999).
Immature DC, tissue-resident, express endocytic receptors for pathogens, such as the 
mannose receptors, DEC-205 and DC-SIGN (Lanzavecchia and Sallusto, 2001). Upon 
activation, the phagocytic ability is downregulated, and cytokine receptor and adhesion 
molecule expression is altered such that activated DC can migrate into secondary 
lymphoid organs (Cumberbatch and Kimber, 1992). Mature DC secrete cytokines that
24
Chapter 1: Background overview
attract naive as well as activated T cells (Adema et al., 1997; Tang and Cyster, 1999), 
and are located in the T cell areas of the secondary lymphoid tissues (Ingulli et al., 
1997). The expression of MHC molecules (Celia et al., 1997; Pierre et al., 1997), and 
the costimulatory molecules CD80 and CD86 (Caux et al., 1994; Sallusto and 
Lanzavecchia, 1994; Turley et al., 2000) is upregulated. These changes enable mature 
DC to prime T cell responses.
DC maturation is a prerequisite for the induction of T cell responses. Immature DCs, 
particularly plasmacytoid dendritic cells (pDCs), produce 1000-fold higher IFN levels 
than other cell types, and are responsible for the systemic IFN-I responses during many 
virus infections (Le Bon and Tough, 2002). IFN-I produced by human monocyte- 
derived DCs or mouse DCs (derived from spleen or bone marrow) has been shown to 
exert autocrine stimulatory effects on the respective DC populations (Luft et al., 1998) 
(Mattei et al., 2001). It has, also, been shown that IFN-I induced during influenza virus 
infection resulted in sustained presentation of MFIC-I/viral peptide complexes to T cells 
by human DCs (Celia et al., 1999b). Exposure to IFN-I induces expression of 
costimulatory molecules such as CD80 and CD86 on DCs facilitating communication 
with T cells during activation (Gallucci et al., 1999; Ito et al., 2001; Santini et al., 
2000). Other activating signals have been reported to be induced, including 1L-15, IL-1 
and TNF-a as well as products generated by cells stimulated with bacterial products 
(Koide et al., 1987; Mattei et al., 2001; Roake et al., 1995; Witmer-Pack et al., 1987).
1.2.4 Cytotoxicity and immunopathology
Both types of killer cells (NK and Tc) use granule exocytosis and Fas-mediated 
pathways to generate their cytolytic attack. The granule exocytosis pathway is the 
principal killing pathway for limiting viral infection in the periphery (Kagi et al., 
1994b). NK cells activity can be increased by cytokines like IL-2 and IFN-y. Their 
granules are preformed, and they can kill their targets within minutes after stimulation 
by activating receptors (reviewed in (Russell and Ley, 2002)). Elevated NK-cytolytic 
activity is present in the spleen early (1-5 days) after viral infections (Biron et al., 1999; 
Karupiah et al., 1992; Mullbacher and King, 1989a). In contrast, naive CD8+T cells 
have no cytolytic activity and they must undergo an activation process that requires
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TCR ligation and costimulation, which then leads to the expression of granule 
components, including perforin and gzms (reviewed in (Russell and Ley, 2002)). 
Signals that activate CD8+T cells also stimulate their proliferation, and virus-immune 
CD8+T cells can expand several orders of magnitude in response to viral infection 
(Doherty and Christensen, 2000). Considering the requirements of activation and 
proliferation of Tc cells to generate their effector function, maximal cytolytic activity is 
reached at about 4 days after peak viral load (Mims and Blanden, 1972). CD8+T cell- 
mediated cytotoxicity following ECTV infection was highest 5-6 days post-infection. $  
response to LCMV infection was first detected at day 6 which peaked at day 8 post­
infection (Zinkemagel and Doherty, 1979).
The Fas pathway of cytotoxicity is similar to that of granule exocytosis mediated killing 
in that maximal expression of the Fas.L requires an initial activation of the effector cell 
(Zheng et al., 1998). In vivo experiments suggest that the granule exocytosis pathway is 
principally involved in target cell lysis via MHC-I Ag presentation pathway and that 
Fas-pathway dominates MHC-II Ag presentation pathway, especially those executed by 
the CD4+T cells (Graubert et al., 1997; Ju et al., 1994; Schulz et al., 1995). Recently, 
however, the Fas-mediated pathway was shown to be the prominent killing pathway by 
CD8+T cells against infected neurons (Medana et al., 2000). An important difference 
between Fas- and exocytosis-initiated pathways is the speed of the cytotoxic event. 
Once formed, granules can be reoriented and released within minutes of TCR 
stimulation (Kupfer et al., 1985). In contrast, very little ligand (e.g., Fas.L) is stored, 
even in activated cells. Therefore, maximal activity requires the synthesis of new 
ligand, which requires 1-2 h after TCR stimulation. Induction of new ligand continues 
as long as there is TCR stimulation, and Fas.L is cleared from the surface either by 
proteolysis or endocytosis, depending on the effector cell. This clearance of Fas.L from 
the surface occurs with a half-life of 2-3 h (Nguyen and Russell, 2001). The long half- 
life of Fas.L on the surface allows effector cells to continue to execute cytotoxic 
activity in the absence of TCR stimulation and leads to the phenomenon of bystander 
killing, which means that cells in contact with effector cells that express Fas can be 
killed even though they do not express nominal Ag recognised by the TCR (Wang et 
al., 1996).
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Despite the important role of both NK and Tc cells in eliminating viral-infected cells, 
their cytolytic activity itself can increase the severity of the infection, as it may lead to 
extensive tissue damage. In fact, immune-mediated cytolytic activity, particularly by Tc 
cells, as a result of viral infection has been associated with tissue injury (Balkow et al., 
2001; Doherty and Zinkernagel, 1974; Guidotti et al., 1999; Kagi et al., 1996; Wang et 
al., 2003). Both LCMV and SFV infections are models for virus-induced Tc cell- 
mediated immunopathology. Infection of immunosuppressed, e.g. severe combined 
immune deficiency (SCID) and cyclophosphamide-treated mice with the neurotropic 
strain LCMV-Armstrong is not lethal compared to lethal encephalitis observed in 
immunocompetent mice, which is characterised by marked cerebral infiltration of 
CD4+T and CD8+T cells (Doherty et al., 1990). Adoptive transfer of virus-immune 
splenocytes into Cy-immunosuppressed mice-infected with LCMV resulted in fatal 
encephalitis, and depletion of CD8+T cells but not CD4+T cells abrogated the ability of 
the adoptive transferred cells to induce the fatal outcome (Dixon et al., 1987). 
Similarly, investigating the immunopathological aspects during SFV infection revealed 
that demyelination is predominantly mediated by CD8+T cells in CBA/C3H and 
BALB/c mice (Fazakerley, 2002; Fazakerley and Webb, 1987a; Subak-Sharpe et al., 
1993).
1.3 Alpha viruses
1.3.1 Members and distribution
The genus Alphavirus, of the family Togaviridae, consists of about 30 members which 
are defined as enveloped single-stranded positive-sense RNA viruses. They have a wide 
host range, but the principal vertebrate hosts are birds, rodents, and primates, with 
infection transmitted by mosquitos (Johnston and Peters, 1996). Alphaviruses, as a 
genus, are globally widely distributed, and some members are serious human and 
animal pathogens. In humans, the severity of alphaviruses infections is extremely 
variable ranging from asymptomatic infection (most infections) to severe encephalitis 
and death. Others are characteristically associated with an acute arthropathy. Thus, 
members of this genus can be classified according to their associated disease as shown 
in table 1.1. The geographic distribution of different viruses within the genus
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Alphavirus is restricted, and human pathogenic alphaviruses can be divided into old 
world viruses (e.g. Sindbis (SIN) and Ross River (RR)) that cause diseases 
characterised by rash and arthritis, and new world viruses (e.g. Eastern, Western, and 
Venezuelan equine encephalitis viruses) that cause encephalitis (Griffin, 1996). In 
Australia, RRV is endemic and epidemic in tropical and temperate regions with Aedes 
mosquitoes the main vectors. Although unknown to be fatal, the discomfort and loss of 
productivity from joint symptoms persist for weeks and occasionally even years.
All alphaviruses have similar morphology and structure, and share a common 
replication strategy. SIN and SFV have been studied extensively, and are the best- 
characterized alphaviruses. Both SIN (reviewed in (Irusta and Hardwick, 2004)), and 
SFV (reviewed in (Atkins et al., 1999; Fazakerley, 2002)) can cause lethal encephalitis 
in mice and have been used as a model for viral neuropathogenesis. The laboratory 
strains of SFV and SIN are considered safe for humans (Strauss and Strauss, 1994).
1.3.2 Structure and replication
Alphaviruses are simple enveloped viruses having a regular virion structure (reviewed 
in (Schlesinger and Schlesinger, 1996; Strauss and Strauss, 1994)). The virion consists 
of one copy of RNA encapsidated in an icosahedral protein shell composed of the 
capsid protein, which is surrounded by a lipid envelope derived from the host plasma 
membrane. The envelope bilayer is penetrated by heterodimers of the viral 
glycoproteins El (50 kDa) and E2 (50 kDa) (reviewed in (Strauss and Strauss, 1994). 
In the case of SFV, a third protein, E3 (10 kDa) is peripherally bound to E1-E2 
heterodimers. El is required for the membrane fusion between the envelope and target 
membrane (Gibbons et al., 2003; Gibbons and Kielian, 2002; Haag et al., 2002; 
Wahlberg and Garoff, 1992), while E2 mediates virus particle attachment to the cell 
surface (Smith et al., 1995; Strauss and Strauss, 1994). The vast host range of 
alphaviruses indicates that these viruses must use a variety of different molecules as 
receptors. In mammalian cells, laminin receptor has been identified as the major 
receptor for SIN (Wang et al., 1992). MHC molecules were reported to be receptors for 
SFV (Helenius et al., 1978), but they are not essential for infectivity (Oldstone et al., 
1980).
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Despite the uncertainty regarding receptor type, alphaviruses have been shown to enter 
cells via receptor-mediated endocytosis (Helenius et ah, 1980; Marsh and Helenius, 
1989). Exposure to low pH in the endosomes results in dissociation of the E1-E2 
heterodimers and concomitant trimerization of the El subunits (Wahlberg et ah, 1992). 
The rearrangement of viral glycoproteins triggers El-membrane fusion activity, and 
allows the nucleocapsid to be released into the cytoplasm (reviewed in (Garoff et ah, 
1994; Kielian, 1995). In the cytoplasm, the binding of nucleocapsid to ribosomes 
mediates viral RNA uncoating (Wengler and Wurkner, 1992).
The genomic RNA (about 12 kb) contains a 5’-terminal cap and a 3’-terminal poly (A) 
tail. It codes for nine functional proteins derived from two open reading frames via 
polyprotein precursors (Figure 1.1) (Kaariainen and Soderlund, 1978). The genome is 
divided into two major regions: a non-structural domain, encoding the non-structural or 
replicase proteins, and forms the 5’-terminal two-thirds of the RNA, and a structural 
domain, encoding the structural proteins of the virus at the 3’-terminal one-third (Figure 
1.1). Following its release into the cytoplasm, the positive-sense genomic viral RNA 
functions as mRNA for translation of the viral nonstructural proteins as a ployprotein 
(PI234) and as a template for the synthesis of the complementary minus strand. After 
translation, this polyprotein is cleaved into four proteins designated as nsPl, nsP2, nsP3 
and nsP4 (reviewed in (Kaariainen and Ahola, 2002)). The nsP4 is the first to be 
cleaved, and forms a complex with PI23 to initiate minus strand RNA synthesis. 
Uncleaved polyprotein PI23 synthesises plus strand, but it is generally cleaved into 
nsPl, nsP2 and nsP3 which in conjunction with nsP4 form the complexes that mediates 
the synthesis of both a new genomic RNA and a 26S subgenomic RNA, from the minus 
strand template.
Structural proteins are translated from the 26S subgenomic RNA as a polyprotein 
containing capsid, P62 (the precursor of E3, E2, and 6K), and El proteins (Strauss and 
Strauss, 1994). Processing of this polyprotein to produce the structural proteins is 
initiated by the autocatalytical release of the capsid protein. This capsid cleavage 
exposes the N-terminal sequence of the P62 which functions as a signal sequence for 
the polyprotein translocation into the ER (Garoff et al., 1990; Melancon and Garoff, 
1987). Translocation of P62 usually results in 6K protein insertion, and the C-terminal
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of 6K mediates the translocation of El (Melancon and Garoff, 1986). Signalase in the 
lumen of the ER mediate appropriate cleavages of the polyprotein into P62 and El. 
These proteins form dimers and traveled through the Golgi complex to the cell surface. 
During transport via the secretory pathway, host cellular enzymes mediate cleavage of 
P62 into E3 and E2, as well as modification of the N-glycans from high mannose-type 
to complex ones (de Curtis and Simons, 1988; Green et al., 1981). In addition, the 
glycoproteins are palmitoylated during the transport (Bonatti et al., 1989; Schmidt, 
1982).
Virus particle assembly is initiated by the encapsidation of the genomic RNA (Figure 
1.2). The capsid protein recognizes and binds the genomic RNA via specific sequences, 
the packaging signal. The packaging signals in alphaviruses are not conserved, and they 
are located in the nsP2 and nsPl genes in SFV and SIN, respectively (Frolova et al., 
1997; Weiss et al., 1989). During viral progeny formation, smaller than normal 
particles in sizes have been reported for SFV (Barrett et al., 1984) and SIN (Johnston et 
al., 1975), and have been referred to as defective interfering (DI) particles. Finally, the 
completion and release of virus particles by budding is driven by specific interactions 
between the nucleocapsid and the cytoplasmic tail of the spike proteins E2 at the 
plasma membrane (Gaedigk-Nitschko and Schlesinger, 1991; Sjoberg and Garoff, 
2003; Suomalainen et al., 1992).
1.3.3 Semliki Forest Virus 
Strains
SFV was first isolated from mosquitoes captured in the Semliki Forest in Uganda in 
1942 (Smithbum and Haddow, 1944), with the original isolate, designated L10, being 
neurovirulent for adult mice causing lethal encephalitis (reviewed in (Atkins et al., 
1999)). Subsequently, non-lethal an avirulent strain, designated A7, was isolated in 
1961 from mosquitoes in Mozambique (McIntosh et al., 1961). Most laboratory strains 
of SFV are derived from these two isolates, and they can be divided according to 
lethality in adult mice into virulent (vSFV), and avirulent (aSFV) (reviewed in 
(Fazakerley, 2002)). The vSFV strains, such as V I3, Osterrieth, and SFV4, were
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derived from L10, whereas The aSFV strains, such as A7(74), and A8, were derived 
from A7 (Bradish et al., 1971; Glasgow et ah, 1991; Liljestrom et ah, 1991; Henderson 
et ah, 1967). Studies comparing vSFV and aSFV strains have shown that both are 
neuroinvasive with lethality being dependent on virulence factor and age of animals. 
While both strains are lethal to neonatal mice, they differ in the extent of replication 
and the associated neuronal damage in older mice (Fleming, 1977; Gates et ah, 1985; 
Pusztai et ah, 1971; Woodward et ah, 1977).
SFV was isolated in 1987 from patients, suffering from fever, severe persistent 
headaches, myalgia, and arthralgia, in the Central African Republic, where it was also 
isolated from locally caught mosquitoes (Mathiot et ah, 1990). Furthermore, 
seroconversion is common in laboratory workers, and there was one fatal 
meningoencephalomyelitis, reported in 1979, associated with the vSFV, Osterrieth 
strain, presence in the brain (Willems et ah, 1979). Experimentally, various strains of 
SFV, capable of infecting voles, mice, guinea pigs, rabbits, and rats, have been used 
(Bradish et ah, 1971; Seamer et ah, 1967).
Virulence
Both vSFV and aSFV are neuroinvasive, and have been shown to infect and probably 
enter the brain by breaching the blood-brain barrier through infecting the cerebral 
endothelial cells (Fazakerley, 2002; Pathak and Webb, 1974; Soilu-Hanninen et ah, 
1994). Within the CNS, the infection spreads from an initial perivascular foci that affect 
oligodendrocytes and glial cells (Balluz et ah, 1993). However, the extent of replication 
and the associated neuronal damage among SFV strains differ according to their 
virulence factor. The vSFV spreads rapidly around the brain, precluding an effective 
immune response, resulting in fatal encephalitis (Fazakerley et ah, 1993). This occurs 
irrespective of the age of the mice. In contrast, the severity of CNS infection with aSFV 
depends on the age of the mice (Fleming, 1977). In neonatal mice, the infection is rapid 
and fatal, similar to that seen with vSFV infection. In older mice, however, aSFV 
becomes less able to spread in the CNS and the infection becomes asymptomatic 
(reviewed in (Fazakerley, 2002)). Generally, the age-dependent asymptomatic infection 
with the aSFV is believed to be a function of CNS cell maturity. The aSFV is able to
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replicate productively in highly active maturing neurons (Oliver et ah, 1997). As 
neurons mature (after 2 weeks), aSFV replication appeared restricted (Fazakerley et al., 
1993; Oliver and Fazakerley, 1998; Oliver et ah, 1997; Pathak and Webb, 1978). The 
differences of aSFV replication have been linked to changes in neuron membranes 
during development. Pre-infection treatment with gold salt, which induces smooth 
membrane production in the neurons, restores lethality of A7 in mice as well as 
unrestricted replication in the brain (Gates et al., 1984; Scallan and Fazakerley, 1999).
Both the vSFV (L10 and SFV4) and the aSFV (A7) strains have been sequenced and 
compared for identification of virulence factors (Glasgow et al., 1994; Santagati et al., 
1994; Santagati et al., 1995; Santagati et al., 1998; Tarbatt et al., 1997; Tuittila et al., 
2000). These studies have found that the untranslated region at the 3’ end of the aSFV 
genome is 334 nucleotides longer than that of vSFV, but it is not an important 
determinant of virulence. Differences in the E2 gene, the nsP3 gene, and the 5’ 
untranslated region of SFV genome may be involved in virulence. Virulence in these 
studies was assessed by lethality in mice without testing possible differences in the 
immune response. It is possible that vSFV and aSFV strains induce different immune 
responses, as serum obtained 6 h after vSFV infection show higher plaque inhibitory 
effect compared to serum obtained after aSFV infection (Fleming, 1977).
Immunopathologv
Virus-induced demyelination has been reported in mice infected with avirulent strains 
of SFV (Chew-Lim et al., 1977). Since virulent strains are lethal to adult mice, 
avirulent strains, particularly A7, was used in almost all of the work investigating this 
aspect of SFV infection. However, any mutation that restricts replication of virulent 
strains in the CNS and allows survival, results in demyelination (Atkins and Sheahan, 
1982; Atkins et al., 1985; Glasgow et al., 1991). Demyelination peaks 14-21 days post­
infection at a time when infectious virus has been cleared from the CNS in CBA/C3H 
and BALB/c mice (Fazakerley, 2002; Fazakerley and Webb, 1987b; Subak-Sharpe et 
al., 1993). Using such mice, depletion studies have indicated a predominant 
immunopathological role of CD8+T cells. The implication of CD8+T cell in 
immunopathology is dependent on the genetic background. B-cell-deficient mice of 
C57BL/6J (B6) background show no white matter vacuolation (or demyelination)
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during avirulent SFV infection despite elevated numbers of CD8+T cells in the brain 
parenchyma (Smith-Norowitz et al., 2000). In fact, Mullbacher and Blanden in 1978 
reported a difference in the induction of CD8+T cells-mediated cytolytic responses to 
alphaviruses (Mullbacher and Blanden, 1978). In that study, splenocytes from both B6 
and BALB/c mice failed to lyse SFV-infected macrophages above background levels 
compared to high killing activity detected for CBA/C3H splenocytes.
Aims of this thesis.
As indicated earlier, the immune response to viral infections is complex and usually 
involves the interplay of many components of both innate and adaptive responses. 
Experiments described in this thesis were aimed at contributing to a greater 
understanding of the immune responses during viral infection, in general, and the 
alphavirus infections of SFV, in particular.
In chapter 2, infections of vSFV and aSFV in adult mice were compared. A difference 
in their ability to induce EFN-I was identified as well as a difference in the efficiency of 
virus growth in spleen and brain.
As SFV infection, particularly aSFV, has been associated with CD8"T cell-mediated 
immunopathology, experiments described in chapter 3 were aimed to explore the 
protective and/or detrimental role of cytolytic effector pathways in SFV infection by 
comparing vSFV lethality in B6 and syngeneic knockout mice. While perfxgzmAB ", 
gld, Fas'", FasxgzmAB" mice showed increased resistance to lethal vSFV infection, 
perf 'xg/d mice showed the most significant resistance which was associated with 
reduced virus replication. Mechanisms for the resistance to SFV of this particular strain 
were explored in chapter 4.
In view of my finding that SFV strains differ in their ability to induce IFN-I, both vSFV 
and aSFV infections were employed in chapters 5 and 6 to explore the 
immunoregulatory effect of IFN-I during viral infection. Such an effect was 
investigated by measuring the expression of the lymphocyte activation markers CD69, 
CD86, and CD25.
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Table 1.1 Alphaviruses and their association with disease (adapted from (Johnston and 
Peters, 1996)).
Disease Epidemics
Acute arthropathy 
Chikungunya (CHIK) +
Mayaro (MAY) +
O’nyong-nyong (ONN) +
Igbo Ora +
Ross River (RR) (epidemic polyarthritis) +
Sindbis +
Ockelbo (Pogosta and Karelian fevers) +
Babanki
Barmah Forest (BF)
Systemic febrile illness (encephalitis) 
Semliki Forest (SFV)
Venezuelan equine encephalitis (VEE)S +
Everglades (EVE)
Mucambo (MUC)
Tonate (TON)
Primarily encephalitis
Eastern equine encephalitis (EEE)a +
Western equine encephalitis (WEE)S +
Highlands J (HJ)b 
No recognized human disease 
Aura (AURA)
Bebaru (BEB)
Buggy Creek 
Cabassou (CAB)
Fort Morgan (FM)
• Getah (GET)3 
Kyzylagach (KYZ) 
Middelburg (MID)
Ndumu (NDU)
Pixuna (PiX)
Sagiyama (SAG) 
Una (UNA) 
Whataroa (WHA)
2 Also causes equine epizootics. 
bRare.
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Figure 1.1. Genome organisation of alphaviruses. The genomic RNA serves as a 
mRNA for the translation of non-structural proteins (nsP). These nsPs function as RNA 
replicase using the genomic RNA as a template for the generation of minus-strand 
RNA, which then used as template for the generation of subgenomic RNA, coding the 
structural proteins, and the complete plus-strand RNA, used in nucleocapsidation 
(adapted from Strauss and Strauss, 1994).
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Figure 1.2. The formation of an alphavirus virion. The structural proteins are translated 
from the subgeneomic RNA as a polyprotein. The capsid protein is released 
cotranslationally by autoproteolysis and assembles to encapsidate the genomic RNA. 
Other structural protein are translocated into the ER, modified, and transported to the 
cell surfase (adapted fromSchlesinger and Schlesinger, 1996).
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2.1 Summary
Ten-week-old B6 mice were infected with virulent and avirulent SFV and lethality, 
peripheral replication, and IFN-I induction assessed. In addition, the effect of 
simultaneous infection with both strains of SFV on lethality was investigated. Both 
strains are neuroinvasive. vSFV, but not aSFV, results in acute infection and early 
death characterised by very high virus titres in the brain. The LD50 for vSFV infection 
< 1 pfu, whereas no mortality occurs with 10 pfu aSFV. Mixed infections comprising 
both strains showed that aSFV protects from lethal vSFV infection in a dose dependent 
manner. High serum levels of IFN-a were detected following vSFV infection compared 
to aSFV. This difference in peripheral IFN-I induction may explain the limited 
replication of vSFV in the spleen compared to that of aSFV.
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2.2 Introduction
SFV is a positive stranded RNA virus of the genus alphavirus, member of the 
Togaviridae family (Strauss and Strauss, 1994). SFV was first isolated from mosquitoes 
in Uganda in 1944 (Smithbum and Haddow, 1944), with the original isolate, designated 
L10, being neurovirulent for adult mice causing lethal encephalitis (Atkins et al., 1999). 
Subsequently, non-lethal an avirulent strain, designated A7, was isolated from 
mosquitoes in Mozambique (McIntosh et al., 1961). Most laboratory strains of SFV are 
derived from these two isolates (Atkins et al., 1999).
Previous work used mainly young mice (5-week-old or younger) to compare the two 
SFV strains for their neurovirulence and lethality (Fleming, 1977; Gates et al., 1985; 
Pusztai et al., 1971; Woodward et al., 1977). Following peripheral infection, these 
studies found that SFV replicates in muscles leading to high-titre viremia detectable 
within 24 h post-infection. Both vSFV and aSFV strains are neuroinvasive, and have 
been shown to infect and most likely enter the brain by breaching the blood-brain 
barrier through the infection of the cerebral endothelial cells (Fazakerley, 2002; Pathak 
and Webb, 1974; Soilu-Hanninen et al., 1994). Within the CNS, the infection spreads 
from an initial perivascular foci that affect* oligodendrocytes and glial cells (Balluz et 
al., 1993). However, the extent of replication and the associated neuronal damage 
among SFV strains differ according to their virulence factor. The vSFV spreads rapidly 
around the brain, resulting in fatal encephalitis (Fazakerley et al., 1993). This occurs 
irrespective of the age of the mice and so rapidly that an effective immune response is 
unable to be generated. In contrast, the severity of CNS infection with aSFV varies 
depending on the age of the mice (Fleming, 1977). In neonatal mice, the infection is 
rapid and ultimately fatal, whereby the virus is able to spread around the brain, similar 
to that seen with vSFV infection. With increas^age, aSFV becomes less able to spread 
in the CNS and the infection becomes asymptomatic. In fact, there is a sharp age­
boundary for virulence: mice infected at 12 days of age or less die, whereas those 
infected at 14 days of age or older survive (Fleming, 1977; Oliver and Fazakerley, 
1998). This age-related virulence may be dependent on the maturity of cells of the 
CNS, as aSFV replicates efficiently in highly active maturing neurons but not in mature 
neurons (reviewed in (Fazakerley, 2002)).
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Furthermore, SFV, like most RNA viruses, generates DI particles during in vitro 
passage at high-multiplicity of infection (Barrett et al., 1984; Bruton and Kennedy, 
1976). These DI particles have been shown to inhibit virus replication, delay the time of 
death, completely protect animals, or convert the infection from lethal to persistent 
when administered either intraperitoneally or intranasally at the same time as vSFV 
(Atkinson et ah, 1986; Barrett et ah, 1984; Dimmock and Kennedy, 1978).
In the present study, 10-week-old mice were used to compare both vSFV and aSFV in 
terms of lethality, peripheral replication, and IFN-I induction. In addition, the effect of 
simultaneous infection with both strains of SFV on lethality was investigated.
2.3 Material and methods
2.3.1 Animals
Wild type (wt) C57BL/6 (B6) mice of either sex were bred under specific-pathogen- 
free conditions and supplied by the Animal Breeding Facilities at the John Curtin 
School of Medical Research, Canberra.
2.3.2 Viruses and cells
Vero (African green monkey kidney), BHK (baby hamster kidney) cells were 
maintained in Eagle's minimal essential medium (EMEM) plus nonessential amino 
acids and 5% foetal calf serum (FCS) and incubated at 37° C in humidified condition 
with 5% CO2.
Virulent SFV and aSFV, used in this study, are most likely to be V I3 and A7, 
respectively (as they were originally obtained from Dr I. Marshal in the early 1980s 
(Woodward et ah, 1977)). Working stocks, of vSFV and aSFV, were prepared by 
infecting semi-confluent BHK cell monolayers at a multiplicity of infection of 0.5 
plaque forming unit (pfu) per cell. Infected cells were incubated for 24h, culture 
supernatants harvested, centrifuged at 1200x g for 4 minutes to remove cell debris, and 
stored in single-use aliquots at -70° C. Titres were 5x 10 pfu/ml for vSFV and 1x10
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pfu/ml for aSFV. Titres were determined by plaque assay on Vero cells. Intravenous 
(i.v) infections were carried out using a final volume of 150pl/mouse.
2.3.3 Plaque assay
Virus was titrated by plaque formation on semi-confluent monolayers of Vero cells as 
previously described (Licon Luna et al., 2002), Samples were serially diluted in Hanks’ 
balanced salt solution (HBSS), pH 7.6 containing 0.2% BSA on ice, and cells infected 
in duplicate with 0.1 ml aliquots of the diluted sample. Adsorption was for 1 h at 37°C 
followed by the addition of an agar overlay medium. After 48h incubation at 37°C, cells 
were fixed with 5% paraformaldehyde (BDH chemicals, Aust.) for lh. Over-layers 
were removed, and fixed cells were stained with 0.2% crystal violet in H2O. The added 
stain was aspirated and plaques counted.
For virus determination of infected mouse tissues, animals were sacrificed at a given 
time post-infection, tissues were aseptically removed, snap-frozen in liquid nitrogen or 
dry ice, and stored at -70°C. 10% (weight/volume) tissue suspensions in ice-cold HBSS 
(pH 7.6) were homogenized, clarified by centrifugation (18,000 x g for 5 min at 4°C), 
and supernatants were stored in aliquots at -70°C. The limit of virus detection in tissues 
and serum of infected mice by plaque titration were 10 pfu/g or ml, respectively. As a 
control, tissues from non-infected animals were homogenised in the presence of a 
known amount of virus. Plaques counted for these samples indicated no loss of 
infectivity after homogenisation.
2.3.4 Serum IFN-a levels
Serum samples were collected from vSFV and aSFV (10 pfu/mouse) infected 10- 
week-old females B6 mice at 0.5, 1, 2, 3, 4, and 5 days post-infection using 2 individual 
mice/time-point. IFN-a levels were tested in these serum samples using sandwich 
ELISA kit according to the manufacturer instructions (USBiological, USA). Briefly, 
100 pi samples were tested for IFN-a concentration using duplicates of the undiluted, 
1/10 and 1/100 dilutions. Samples were incubated for 1 h, washed twice, and anti­
mouse IFN-a antibody was, then, added and incubated at room temperature (all 
incubations carried out at this temperature). After 24 h, plate was washed 4 times and 
HRP-conjugate was added and incubated for lh. Then, plate was washed 4 times and
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TMB substrate was added (100 pl/well) and incubated for 15 min in the dark. Reaction 
was stopped with lOOpl of stop solution (provided), and absorbance at 405nm was 
measured. Serum IFN-a concentrations were estimated and expressed as pg/ml. In each 
experiment, a standard curve measuring 0-500 pg/ml was generated from the provided 
mouse IFN-a. The detection limit of IFN-a concentration in tested samples was 12.5 
pg/ml.
2.4 Results
2.4.1 Lethality of vSFV versus aSFY
10-week-old female B6 mice were infected i.v with different doses of either vSFV or 
aSFV and survival was monitored for a 21-day period. The vSFV strain was very lethal 
with 60% mortality at a dose of 10° pfu/mouse, and 100% mortality at 101 or more 
pfu/mouse (figure 2.1). This compares with 100% survival when aSFV at 10 
pfu/mouse was used (figure 2.1).
2.4.2 Tissue viral titres
In order to understand the difference between both SFV strains, virus titres in brain, 
spleen, and serum were estimated at different times post-infection. Pre-designated 
groups of mice were infected i.v with 103 pfu of either vSFV or aSFV. Mice were 
sacrificed at given time point, and virus titres determined by plaque assay as pfu/g for 
brain, and spleen, or pfu/ml for serum (figure 2.2). Both SFV strains were detectable at 
day 1 post-infection in all tested tissues. Virus titres differed in both brain and spleen 
between the two strains. The vSFV replicated to high titres in the brain reaching >10 
pfu/g by day 5 post-infection (figure 2.2.A). A similar observation was previously 
described (reviewed in (Fazakerley, 2002)). This compares with brain titres of 5x104 
pfu/g when aSFV was used (figure 2.2.A). This low brain titre is a distinct feature of 
aSFV infection where replication is restricted in neurons, as has been shown previously 
by a number of studies (Fleming, 1977; Gates et al., 1985; Pusztai et al., 1971; 
Woodward et al., 1977). By contrast the data presented here for spleen titres indicated a 
different picture than that seen in the brain (figure 2.2.B). Despite similar titres for both 
strains detected at day 1 post-infection, they differed at day 3 with aSFV replicating 
more preferentially whereby reaching more than 106 pfu/g compared to vSFV titres
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which did not increase above the detected titre for day 1 post-infection. This difference 
in spleen titres seen for vSFV and aSFV was not affected by virus level in the blood as 
limited serum titres detected for both strains at day 3 post-infection (figure 2.2.C).
2.4.3 Serum IFN-a levels
n #
Serum was collected from mice infected with 10 pfu/mouse vSFV or aSFV at various 
times post-infection and individually tested for the concentration of IFN-a using 
sandwich ELISA as described in methods. As shown in figure 2.3, elevated IFN-a 
levels, induced by vSFV infection, were first detected 12 h post-infection, peaked at 24 
h (2900 ± 100 pg/ml) and declined to background levels by day 3 post-infection. Using 
the same dose of aSFV, significant levels of serum IFN-a were detectable at 24 h post­
infection, peaking at 48 h (875 ± 25 pg/ml) and then declined. Peak levels were 
substantially lower than that observed with vSFV. Increasing the dose of aSFV by 4 
logs to 107 pfu produced qualitatively and quantitatively similar results U  that observed 
with i03 pfu vSFV.
2.4.4 Protection against lethal vSFV by non-lethal aSFV
Adoptive transfer of immune cells (total splenocytes) from aSFV-infected mice has
been reported to protect against lethal vSFV (Kraaijeveld et al., 1986). Ten-week-old 
B6 mice were immunised with 103 pfu/mouse aSFV. Five months later, these mice 
were challenge with either 1 or 103 pfu vSFV. The survival of these mice was 
compared to same age unprimed mice (figure 2.4). As shown before, unprimed mice 
succumbed to an infection with 103 pfu vSFV with 100% mortality and 20% death rate
3with 1 pfu. In comparison, no mortality was observed in mice primed with aSFV (10 
pfu/mouse) with either challenging dose.
Furthermore, previous investigators argued that both strains of SFV have similar 
tropism but variable rates of replication, at least in neurons (Balluz et al., 1993; 
Fazakerley et al., 1993). Therefore, it was of interest to investigate the effect of mixed 
infections on the virulence of vSFV. Figure 2.5 shows that aSFV protects the mice 
when given simultaneously with otherwise lethal doses of vSFV. Mice were protected 
from 1 pfu vSFV infection by aSFV in a dose dependent manner (figure 2.5.A). 
Administration of 107 pfu aSFV and increasing doses of vSFV lead to an increased 
mortality (figure 2.5.B).
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2,4.5 Role of IFN-I in protection against lethal vSFY infection
To address if IFN-I induced by aSFV (107 pfu/mouse) infection was responsible for the
protection from vSFV, poly I.C, the IFN-I inducer, was injected intraperitoneally at the 
same time as infection with vSFV (103 pfu/mouse) and survival of these mice was 
monitored (figure 2.6). Poly I.C treatment affected the lethality of vSFV in a dose 
dependent manner. Injection of 0.1 mg/mouse poly I.C increased the survival rate from 
0% to 20%, doubling the dose to 0.2 mg/mouse increased the survival rate to 50%, 
suggesting a possible IFN-I mediated cause for the protective effect of aSFV in 
susceptibility to vSFV infection.
2.5 Discussion
The data presented here describe experiments comparing the two strains of SFV in 
regard to their virulence, tissue tropism, replication capacity and ability to induce IFN- 
I. The two strains are vastly different in their virulence. Virulent SFV has a LD50 of < 1 
pfu, conversely 107 pfu aSFV does not result in mortality in 10-week-old B6 mice. 
Similar results have been reported previously (Fleming, 1977).
When virus load was determined in various tissues over an 8-day period post-infection 
with 103 pfu of either strain of SFV, peripheral replication was higher with aSFV than 
virulent. This was especially prominent in the spleen but was also evident in blood. 
However, the reverse was true for virus titres in the brain. At day 1 post-infection, 
vSFV could be detected in brain tissue and increased till the death of animals. This 
contrasts with aSFV which was present in the brain at day 3 but declined to 
undetectable levels by day 7 post-infection. Brain titres were above that which possibly 
could have been due to blood borne virus. Thus both strains of virus have the ability to 
cross the blood-brain barrier but only vSFV replicates to high titres. Replication of 
aSFV is either controlled by the hosts’ immune response or replication is self-limiting 
in the CNS tissues. Earlier work by Barrett and colleagues suggest that defective 
interfering particles may be responsible for the different growth characteristics of the 
two strains of SFV (Barrett et al., 1984). Therefore, the protective effect of co-infection 
of aSFV on vSFV-mediated mortality may be due to defective interfering particles in 
the preparation of aSFV stock.
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Surprisingly, the vSFV strain was the superior inducer of IFN-I in the periphery, which 
may explain vSFV limited replication in the spleen compared to that of aSFV. This 
effect may predominantly be due to IFN-a which appears not to be operative in brain 
where IFN-ß is active (Sandberg et al., 1994). However, more complex immune 
mediated mechanisms of the innate immune system cannot be ruled out, and the role of 
IFN-II and early NK cell responses have in limiting aSFV but not vSFV replication in 
brain is not known.
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Figure 2.1: Mortality of 10-week-old B6 mice given vSFV or aSFV. Mice were given
o n
1-10 pfu vSFV or 10 pfu aSFV i.v and mortality recorded for 21 days. No death was 
recorded beyond day 10 post-infection.
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Figure 2.2 : Virus titres in brain (A), spleen (B), and serum (C) after infection with 10 
pfu aSFV or vSFV. Three individual animals per strain were assayed 1-7 days post- 
infection. Detection limit was 10 pfu/g tissue or ml serum.
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Figure 2.3: Serum IFN-a levels were tested following infection with either vSFV (103 
pfu) or aSFV (103 or 107 pfu). Two mice per day (per group) were tested individually 
for their respected serum IFN-a concentrations and mean results were expressed as 
pg/ml. The detection limit is 12.5 pg/ml.
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Figure 2.4: Early non-lethal aSFV infection protects against late lethal vSFV. Mice 
primed with aSFV (10 pfu/mouse) were compared to naive mice in their sensitivity to 
vSFV using infection with either 1 or 10 pfu/mouse.
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Figure 2.6: The role of IFN-I inducer in protection from vSFV. 10J pfu vSFV was 
combined with i.p injection of poly l.C (0.1 or 0.2 mg/mouse). Survival of these mice 
monitored for 21 days and compared to that seen during either doses of vSFV alone, or 
mixed vSFV and aSFV infections.
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Figure 2.6: The role of IFN-I inducer in protection from vSFV. 10J pfu vSFV was 
combined with i.p injection of poly I.C (0.1 or 0.2 mg/mouse). Survival of these mice 
monitored for 21 days and compared to that seen during either doses of vSFV alone, or 
mixed vSFV and aSFV infections.
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3.1 Summary
NK and Tc cells are prime effector populations in the antiviral response of the host. Tc 
cells are essential for recovery from many viral diseases but may also be responsible for 
immunopathology. The role of NK cells in recovery from viral infections is less well 
established. I have studied the acute vSFV infection of the CNS in B6 mice, which 
spares Tc cells and is mainly controlled by NK cells. Results presented in this chapter 
show that mice with defects in the Fas and/or granule exocytosis pathways of 
cytotoxicity were more resistant to lethal vSFV infection than wt B6 mice. On the other 
hand, mice defective in IFN-y response are more sensitive than wt mice, whereas mice 
lacking the Tc cell compartment (ß/2 microglobulin) exhibit susceptibility similar to wt 
mice. The additional findings that depletion of NK cells significantly delayed the MTD 
but did not prevent mortality in SFV infected B6 mice suggests that cytolytic activity of 
NK cells is detrimental while IFN-y production is beneficial for recovery from SFV 
infection. This study illustrates, for the first time, a NK cell-mediated 
immunopathological outcome to an acute viral infection executed primarily via the Fas 
and exocytosis pathways.
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3.2 Introduction
Efficient early control of viral infections is determined by viral tissue tropism and rate 
of replication, and the host’s ability to mount an effective immune response. Cellular 
cytotoxicity, in particular that of NK and Tc cells, is central to the early antiviral 
immune response. Both effector cells, can execute apoptotic processes in virus infected 
targets via either Fas-mediated or granule exocytosis pathways (Trapani and Smyth, 
2002) in addition to the secretion of cytokines such as IFN-y, TNF-a, and interleukins 
(Boehm et al., 1997; Vassalli et al., 1992). The Fas-mediated pathway of cytotoxicity 
involves the binding of Fas.L expressed by activated Tc and NK cells to Fas receptors 
on target cells and leads to apoptosis of target cells via the caspase cascade (Kagi et al., 
1996). The granule exocytosis pathway involves secretion of perf and at least two 
gzms, gzmA and gzmB (Trapani and Smyth, 2002), contained within cytoplasmic 
granules of effector cells (Russell and Ley, 2002). Granzymes may enter target cells 
independent of perf by receptor-mediated endocytosis, but must act in concert with perf 
in the cytoplasm to cause cell death via caspase-dependent or -independent apoptosis 
(Russell and Ley, 2002; Trapani and Smyth, 2002), Immune mediated cytolytic 
activity as a result of viral infection has been associated with tissue injury (Balkow et 
al., 2001; Doherty and Zinkernagel, 1974; Guidotti et al., 1999; Kagi et al., 1996; Wang 
et al., 2003).
Since vSFV is lethal to adult mice, aSFV was used in almost all of the work 
investigating immunopathological aspects during this viral infection. Demyelination, 
peaking 14-21 days post-infection with aSFV, is predominantly mediated by CD8+T 
cells in CBA/C3H (H-2k) and BALB/c (H-2d) mice (Fazakerley, 2002; Fazakerley and 
Webb, 1987; Subak-Sharpe et al., 1993). However, cytotoxic CD8+T cells responses to 
alphaviruses have so far only been associated with the MHC class I allele H-2Dk 
(Mullbacher and Blanden, 1978), Raising the question by which mechanism 
demyelination occurs in infected BALB/c mice in the absence of a responder H-2 
allele. Additional support for a lack of CD8+T cell involvement in alphavirus infection 
of some inbred mouse strains comes from B-cell-deficient mice of the H-2b haplotype 
(B6 mice). These mice show no white matter vacuolation during avirulent SFV 
infection despite elevated numbers of CD8+T cells in the brain parenchyma (Smith-
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Norowitz et al., 2000). In addition, T cell depletion (both CD4+ and CD8+) in B6 mice 
does not alter the outcome of lethal vSFV infection (Doherty, 1973). This together with 
the observation that perf deficiency does not lead to increased susceptibility of B6 mice 
to aSFV infections (Kagi et al., 1995b), lead to the assumption that death during vSFV 
infections is the result of neuronal damage caused by extensive viral replication rather 
than immunopathology (Atkins et al., 1999).
The possibility that other effector cells, such as NK cells, which have been implicated 
before in the control of various virus infections (Biron et al., 1999), contribute to SFV- 
induced pathology has not been excluded. In fact, it was shown that SFV infection 
leads to the activation of high levels of NK cell-mediated cytotoxicity (Mullbacher and 
King, 1989b). Maximal NK activity is observed early during infection and prior to T 
and B cell responses (Biron et al., 1999). Thus, the possible involvement of NK cell- 
mediated cytolytic activity(ies) in immunopathology during vSFV infections has been 
investigated.
3.3 Material and methods
3.3.1 Viruses and cells
Vero, BHK, the NK cell-sensitiveYAC-1 thymoma, the NK cell-resistant P815 
mastocytoma, and the methylcholanthrane-induced fibroblast lines MC57 (H-2b), and 
L929 (H-2k) were maintained in EMEM plus nonessential amino acids and 5% FCS and 
grown at 37° C in humidified condition with 5% CO2.
Working stocks for vSFV and aSFV were prepared by infecting semi-confluent BHK 
cell monolayers at a multiplicity of 0.5 pfu per cell. Infected cells were incubated for 24 
h, culture supernatants harvested, centrifuged at 1200 x g for 4 min to remove cell 
debris, and stored in single-use aliquots at -70° C. Titres determined by plaque assay on 
Vero cells were 5 x 107 pfu/ml for vSFV and 1 x 108 pfu/ml for aSFV. Animal 
infection$were i.v with a final volume of 150pl/mouse.
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3.3.2 Animals
CBA/H (H-2k), C57BL/6 (H-2b) (B6) mice, B6 syngeneic mice deficient in the 
exocytosis pathway involving gene knockouts of perforin (perf7') (Kagi et al., 1994a), 
gzm A (gzmA'7') (Ebnet et al., 1995), gzm B (gzmB'7') (Heusel et al., 1994), gzm A and 
B (gzmAB'7') (Simon et al., 1997), or gzm A and B plus perforin (perfxgzmAB"7') 
(Mullbacher et al., 1999b), and syngeneic mice deficient in the Fas-mediated cytolytic 
pathway involving either a loss-of-function mutations in the Fas receptor (CD95, Fas) 
(lpr) (Samelson et al., 1986) or Fas ligand (Fas-L) (gld) (Takahashi et al., 1994), or Fas 
receptor (Fas'7") gene knockout by targeted mutation (Adachi et al., 1995), were used. 
Mice deficient in both pathways were either Fas and gzm A and B negative 
(FasxgzmAB'7') (Rode M, 2004), or deficient in perforin and Fas-L (perf7'xgld). Perf7' 
xgld mice were generated by cross breeding mice heterozygous for perforin and 
homozygous for the Fas.L mutation, as previously described (Licon Luna et al., 2002). 
In addition, I used ß-2 microglobulin targeted mutant mice (ß2M"7') (Koller et al., 1990) 
that lack cell surface expression of MHC-I, the thymic selecting element for CD8+T 
cells. In addition, interferon (IFN)-y knockout (IFN-y'7') mice (B6 genetic background) 
(Tagawa et al., 1997), and interferon (IFN)-y-receptor knockout (IFN-yR'7) (Huang et 
al., 1993) mice and their wild-type 129T2/Sv (129) strain were used.
Mice were bred under specific pathogen-free conditions and supplied by the Animal 
Breeding Facilities at the John Curtin School of Medical Research, Canberra.
3.3.3 51Cr Release Cytotoxic Assay
Assays for both NK cells-mediated (Mullbacher and King, 1989b) and Tc cell-mediated 
cytotoxicity (Mullbacher and King, 1989a) have been previously described. In brief, 
mice were infected with 1 pfu vSFV and splenocytes harvested at predetermined time 
pi tested for NK cell-mediated cytotoxicity on 51Cr labelled YAC-1 and P815 target 
cells. For Tc cell-mediated cytotoxicity assays B6 and CBA mice were infected with 
103 pfu aSFV. Memory splenocytes were restimulated in vitro with SFV-infected 
syngeneic splenocytes. Control alloreactive Tc cells were generated by co-culture of 
either B6 or CBA splenocytes with 2000 rad irradiated CBA or B6 stimulator cells, 
respectively, for 5 days at a responder to stimulator ratio of 3:1.
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3.3.4 In vivo NK cell-depletion
B6 mice were injected i.p with 30 pi rabbit anti-asialo GM1 antiserum (Wako) at -4, - 
2, 0 (day of infection), 2, 5, and 8 days post-infection. NK cell-mediated cytotoxicity of 
splenocytes from treated and untreated mice was measured at day 3 pi to test for 
successful NK cell depletion.
3.3.5 Statistical analysis
All statistical analyses were conducted using GraphPad InStat software. Fisher’s exact 
test was used to compare survival rates and the Mann Whitney test was used to 
compare mean times to death (MTD).
3.4 Results
3.4.1 Dose response of vSFV in wild-type B6 mice
Results presented in chapter 2 showed that survival rates of B6 mice infected i.v with 
103 to 1 pfu vSFV were dose-dependent with 40% survival in the group infected with 1 
pfu/mouse, and no surviving mice in groups infected with doses of 10 pfu or higher.
To assess the infectivity in mice of 1 Vero cell pfu vSFV, 3 groups of 10 females B6 
mice (4 weeks old) were injected intracranially (i.c) with 10"1, 10'2, and 10'3 pfu/mouse 
of vSFV. This resulted in 100%, 60%, and 10% mortality, respectively (figure 3.1), and 
indicates that 1 Vero cell pfu is equivalent to 102-103 mouse infectious doses. 
Accordingly, 1 Vero cell pfu was used as the standard dose to compare the lethality of 
vSFV infection in B6 and syngeneic mice with deficiencies in cytolytic pathways.
3.4.2 Mortality of cytolytic effector pathway defective mice to vSFV 
infection
10-week-old female B6, perf7', gzmA'7', gzmB'7', gzmAB'7', perfxgzmAB'7', lpr, gld, 
Fas'7', FasxgzmAB'7', and perf7'xgld mice were infected i.v with 1 pfu vSFV. Clinical 
signs associated with vSFV infection, such as ruffled fur, hunched posture, impaired 
movement leading to paralysis were similar in B6 and all defective mice, with the 
exception of perf7'xgld mice which showed no paralysis. The survival of these mice
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was monitored for a 21-day period. The cumulative results from a number of 
experiments are shown in table 3.1. The survival rate of B6 mice was 30%. All mice 
defective in one of the cytolytic effector functions showed higher survival rates where a 
defect in the granule exocytosis pathway (gzmA'7', gzmB'7', perf7', gzmAB'7') increased 
the resistance to SFV marginally and a defect in the Fas pathway (gld, and Fas'7') 
resulted in a significant increase in survival (P=0.012 and 0.014, respectively) relative 
to B6 mice. The discrepancy between the Toss of function’ mutant lpr and ‘knockout’ 
mutant Fas'7" strains in susceptibility to SFV infection is most likely due to “leakiness” 
in the Fas defect in lpr mice (Nagata and Suda, 1995). Mice defective in both granule 
exocytosis- and Fas- mediated pathways of cytotoxicity (FasxgzmAB'7', and perf7'xgld) 
were the least susceptible to vSFV infection; the survival results were 65% and 78%, 
respectively, and the increase in survival was significant relevant to B6 mice. A 
significant increase in MTD in groups of Fas'7' (10 days), FasxgzmAB'7' (9.3 days), and 
perf7'xgld (12.2 days) in comparison to B6 mice (7.3 day) was also observed (table 1).
3.4.3 Tc cell- mediated cytotoxic activity to vSFV infection
To asses whether the increase in survival rates seen in cytolytic function deficient mice
was due to impaired cytolytic activity of Tc cells, ß2M'7' mice which lack CD8+ T cells 
were infected with vSFV and their survival monitored for 21 days. ß2M'/_ mice were 
similar to B6 mice in their sensitivity to vSFV infection, with an almost identical MTD 
and survival rate (Table 3.1). This strongly indicates that CD8+ Tc cells are not 
responsible for the higher mortality rate of B6 mice relative to mice with defects in one 
or more of the cytolytic effector pathways of NK and Tc cells.
In addition, the level of CD8+ Tc cell cytotoxic activity induced as a result of SFV 
infection in B6 (H-2b) mice was examined. Mice were infected with aSFV 2 weeks 
prior to in vitro boosting with aSFV-infected syngeneic splenocytes for 5 days to 
optimise induction of cytolytic Tc cell activity. SFV-immune B6 effectors and control 
CBA (H-2k) SFV-immune effectors together with anti- H-2b and anti- H-2k alloreactive 
control effectors were assayed on SFV infected and uninfected MC57 (H-2b) and L929 
(H-2k) target cells using a 6h 51Cr release assay (Table 3.2). My data confirm 
previously published data (Mullbacher and Blanden, 1978) that B6 mice do not respond 
to SFV infections with a cytotoxic T cell response under conditions that generate 
cytotoxic responses in CBA (H-2k) mice. This is further evidence that CD8+Tc cells are
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not involved in cytolytic effector molecule-mediated immune pathology during SFV 
infections.
3.4.4 NK cell-mediated cytotoxic activity
To asses the strength of the NK cell response, B6 mice were infected i.v with 1 pfu 
vSFV 1-5 days prior to testing their splenocytes in vitro for cytolytic activity on YAC-1 
and P815 target cells using a 6h ?1Cr release assay. SFV infection induced high NK 
cell-mediated cytotoxicity against YAC-1 targets, which peaked by day 3 post-infection 
(figure 3.2.A). No cytotoxic activity was detected on the NK cell resistant P815 targets.
3.4.5 NK cell-depletion and its effect on vSFV infection
Since mice defective in cytolytic effector molecules show increased resistant to vSFV
infection, and a detrimental effect of CD8+ Tc cells in SFV infection could be excluded, 
NK cell-mediated cytotoxicity was investigated to determine if it is responsible for the 
immune-mediated increase in mortality. B6 mice were depleted of NK cells by multiple 
injections of anti-asialo GM1 anti-serum. Depletion of the NK cell population in 
spleens was monitored using the 51Cr release assay on YAC-1 target cells at day 3 after 
SFV infection. Depletion reduced lysis of YAC-1 targets below that obtained with 
naive splenocytes (Fig 3.2.B). B6 (n=8) mice were subjected to the NK cell-depletion 
protocol and infected with vSFV (1 pfu). Survival of these mice was monitored and 
compared to that of untreated control mice (Figure 3.3). B6 mice showed an average 
survival time of 6 ± 0.8 days compared to 11.1 ±2.1 for NK cell-depleted mice (P= 
0.0139). Interestingly, death in NK cell-depleted mice was not associated with hindlimb 
paralysis, which is a consistent clinical feature associated with death in B6 mice from 
vSFV infection. The overall mortality of NK cell-depleted mice, however, was higher 
compared to that of untreated B6 mice (88% and 50%, respectively).
3.4.6 Role of IFN-y in vSFV infection
To address whether reduced levels of IFN-y in NK cell-depleted SFV infected mice 
played a role in their increased mortality relative to infected B6 mice, I compared the 
mortality of IFN-y'7' and IFN-yR'7' mice following vSFV infection to that of their wild 
type counterparts B6 and 129/sv, respectively. Groups (n=20) of 10-week-old female 
wt B6, wt 129/sv, IFN-y'7', and IFN-yR'7' mice were i.v injected with 1 pfu/mouse 
vSFV. Survival of these mice was monitored for 21 days. Five percent of IFN-y'7'
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compared to 35% B6 mice, and 55% of IFN-yR’7' compared to 90% of 129 mice 
survived (figure 3.4). IFN-y'7' mice were significantly less resistant to vSFV than B6 
mice (P= 0.0436), and IFN-yR"' mice were significantly less resistant to vSFV than 129 
mice (P= 0.0310). 129 mice were significantly more resistant to vSFV infection 
compared to B6 mice (P= 0.0008).
3.5 Discussion
CD8+T cells-mediated immunopathogensis during aSFV infection resulting in 
demyelination has been reported in CBA/C3H and BALB/c mice (Fazakerley and 
Webb, 1987; Subak-Sharpe et al., 1993). B cell-deficient B6 mice, however, show no 
white matter vacuolation despite elevated CD8+T cells levels (Smith-Norowitz et al., 
2000). In addition, SFV-infected B6 mice are non-responders in Tc cell assay with 
respect to SFV-infected target cell lysis (Mullbacher and Blanden, 1978). It was, thus, 
of interest to investigate if cytolytic effector molecules are at all involved in recovery or 
immunopathogenesis during SFV infection in B6 mice. The lethality due to vSFV 
infection as an indicator of such an involvement was utilised and mice defective in 
cytolytic effector function wcrn* found to be more resistant to challenge with vSFV. This 
clearly suggests an immunopathological aetiology in SFV-infected B6 mice. In 
comparing the role played by molecules involved in the Fas versus granule exocytosis 
pathways of cytotoxicity, defects in the Fas pathway exhibit a stronger phenotype. This 
is not entirely unexpected, given that SFV has been reported to infect a wide variety of 
cells especially neurons and oligodendrocytes (Fazakerley, 2002), and given the 
dominant role of Fas-mediated cytotoxicity in neuronal apoptosis (Medana et al., 
2000). Furthermore, Fas.L expressed on neurons provides protection against perf attack 
(Medana et al., 2001). The latter is consistent with our finding that mice defective in the 
Fas.L (gld) have a significantly shorter survival time than Fas'7' mice (Table 1).
Perforin has been shown to play a crucial role in the recovery of mice from some (Kagi 
et al., 1994; Mullbacher et al., 1999a; Riera et al., 2000) but not other (Elkon et al., 
1997; Kagi et al., 1995b; Wang et al., 2004) viral infections, and in some cases the lack 
of perf was beneficial in recovery (Licon Luna et al., 2002; Mullbacher et al., 1999a).
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Hence this data demonstrates that lack of perf and gzms (perfxgzmAB'7') significantly 
augments survival from vSFV infection and those single gene knockouts in the granule 
exocytosis pathway result in a trend towards increased survival relative to B6 mice 
(Table 3.1). Interestingly, mice lacking both Fas- and granule exocytosis-mediated 
cytotoxicity (FasxgzmAB'', and perf/_xgld) were most resistant to the low dose of 
vSFV infection, demonstrating redundancy, in this case in the pathogenic potential, of 
the two cytotoxic pathways. Nevertheless, some double-deficient mice did succumb to 
SFV infection suggesting multiple determinants of disease outcome, which most likely 
involve the interplay of immune-mediated and virus-mediated pathology. The 
combined involvement of both cytolytic pathways in immunopathology has also been 
shown in LCMV associated viral hepatitis (Balkow et al., 2001) and Murray Valley 
encephalitis (Licon Luna et ah, 2002).
Cellular cytotoxicity in response to viral infections generally involves an early NK cell 
response followed by Tc cell activation (Biron et ah, 1999; Mullbacher and King, 
1989b). With a MTD of 7 days in B6 mice after vSFV infection, it is unlikely that Tc 
cell are responsible for the observed mortality. This indicates that NK cell-mediated 
cytotoxicity may be responsible for the immunopathology during vSFV infections.
Mice defective in CD8+T cells, ß2M7' mice, were as sensitive as B6 mice to vSFV 
infection (Table 1) confirming earlier work showing that CD8+T cell depletion did not 
alter the outcome of vSFV infection (Doherty, 1973). In addition, early observations 
that B6 mice are Tc cell nonresponders in regard to lysis of target cells infected with 
SFV (Mullbacher and Blanden, 1978), a result which was confirmed here (Table 2), 
also support the conclusion that Tc cell-mediated is not involved in immunopathology. 
This conclusion is further supported by the fact that B cell-deficient B6 mice did not 
show myelin injury despite the presence of elevated numbers of CD8+T cells in the 
CNS (Smith-Norowitz et al., 2000).
SFV is a potent inducer of NK cell lytic activity with peak cytolytic activity at days 2-3 
post infection ((Fig 2) and (Mullbacher and King, 1989b)). The crucial experiment that 
implicated NK cells in immunopathology during vSFV infection was the effect of NK 
cell-depletion on the outcome of vSFV infection. Depletion of NK cells by 
intraperitoneal administration of anti-asialo GM1 serum significantly extended the
61
Chapter 3: Immunopathology
average survival time following vSFV infection. This indicates that NK cells contribute 
to the early death in B6 mice. However, since vSFV is a cytopathic virus replicating to 
high titres in the brain of infected mice (Pusztai et al., 1971), depletion of NK cells is 
not expected to prevent virus-mediated cytopathology. The increased mortality of NK 
cell-depleted mice indicates that anti-asialo GM1 treatment may have compromised a 
beneficial effector function of NK cells. Activated NK cells secrete cytokines with 
direct as well as indirect anti-viral activity, including IFN-y. The present data on 
mortality and MTD of mice deficient in IFN-y or lacking the IFN-y receptor does 
support the notion that the increased mortality following NK cell-depletion may be due 
to decreased IFN-y secretion. A more definitive approach to illustrate the beneficial role 
of IFN-y and the detrimental effect of cell-mediated cytotoxicity during vSFV infection 
would require the generation of Fas, gzmA, gzmB, and IFN-y quadruple-deficient mice: 
these would be predicted to be more sensitive to SFV infection than B6 mice and 
display a delayed MTD. In conclusion, this is the first study indicating to the role of the 
cytotoxic activity of NK cells in immunopathology during a viral infection, with the 
Fas pathway playing the critical role. It will be important to re-examine other models of 
viral infection with immunopathological manifestations to see if part of the aetiology is 
NK cell-mediated.
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Table 3.1: Mortality and mean time to death of mice defective in granule exocytosis- 
and/or fas-mediated cytolytic effector pathways, or ß2M’/' mice as a consequence of 
vSFV infection.
Strain Number
% Survival*
(P  v a l u e ) @
MTD ± S.D *
(P  v a l u e ) 8.
B6 39 30 .7 7.3 ± 1 .5
gzmA''- 33 36  (0 .6 2 8 ) 6 .9  ± 0 .9  (0 .6 9 1 )
p erf'’ 43 42  (0 .3 6 1 ) 7 .7  ± 2 .2  (0 .7 0 6 )
gzm B'* 4 4 45  (0 .1 8 4 ) 7 .7  ± 1 .5  (0 .3 0 2 )
gzmAB'" 52 4 6  (0 .1 9 4 ) 8.3 ± 1 .9  (0 .0 7 8 )
Ipr 42 50  (0 .1 1 3 ) 7 .7  ± 1 .6  (0 .4 3 5 )
perfxgzm AB'' 45 56 (0 .0 2 8 ) 6 .9  ± 1 .5  (0 .5 3 2 )
gld 39 62  (0 .0 1 2 ) 7 .3 ± 1 .4  (0 .7 4 2 )
F as '’ 2 9 62  (0 .0 1 4 ) 10 ± 3 .2  (0 .0 0 8 )
FasxgzmAB''- 31 65 (0 .0 0 7 ) 9 .3 ± 2 .7  (0 .0 3 3 )
p erf'xg ld 23 78 ro .oon 12.2 ± 2 .2  (0 .0 0 1 )
ß2M"/' 38 29  (1) 7 .3 ± 1 .2  (0 .5 4 9 )
* Percentage survival rates after i.v infection with 1 pfu vSFV
® P values obtained from Fisher Exact test comparing survival rates, significant 
difference is underlined.
# Mean time to death ± standard deviation
& P values obtained from Mann-Whitney test comparing MTD, significant difference is 
underlined.
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Table 3.2: Lack of SFV-immune cytolytic T cell response in B6 mice
Effectors E :T M C 57-
m ock
% Specific  targe ts  cell lysis  ± SEM * 
M C 57-S FV  L929-m ock L929-S FV
30 3.3  ± 2.0 2 .5  ± 0.9 15.9  ±  1.6 1 1 .4 + 1.5
B 6.an ti-
SFV*
10 1.1 ± 0.3 1.0  ±  0.8 7 .4  ± 0.5 7 .4  ± 1.3
3 0 .3  ± 1.4 0 .3  ± 0.6 5.1 ±  1.2 2 .6  ± 0.9
30 4 . 5 ± 1.6 4 .7  ± 1.5 37 .2  ± 2.7 29.1  ± 2 .9
B 6.anti-
10 1.3  ± 1.3 1.3 ± 1.3 2 8 .6  ±  1.7 16.6  ± 1.3
C B A
3 0.2  ± 0.2 0.0  ± 0.3 19.2  ± 0.9 5.1 ±  1.2
30 7 .3  ±  1.0 8.1 ± 1.3 11.2  ±  0.7 32 .5  ± 2 .5
C B A .an ti-
SFV*
10 3.0  ± 0.4 2 .9  ± 0.1 8 .3  ± 0.6 17.5  ± 0.5
3 1.4  ± 2.6 2 .3  ± 2.6 4 .3  ± 2.6 7 .4  ± 0.9
30 39 .8  ± 2.8 35.8  ± 1.2 13.7  ± 3.5 14.7  ± 2.1
C B A .an ti-
10 20 .9  ± 3.6 17.4  ± 0.7 6 .4  ± 0.3 8 .9  ± 2.2
B6
3 7.7  ±  1.7 9.7  ±  1.5 3 .3  ± 0.9 4.1 ± 0.7
* Percent5'Cr release of target cells over a 6 h period. Mean of triplicates with SEM 
given.
n
Secondary' responses generated in vitro 2 wk after priming as described (Mullbacher 
and Blanden, 1978).
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1 0 0 -
d 40-
Days post-infection
10'3 pfu 
■ * —  10'2 pfu 
* -  10‘1 pfu
Figure 3.1: Dose response to vSFV infection in B6 mice where groups of 4-week-old
1 o
mice (n 10) infected i.c with 10‘ -10‘ pfu/mouse. Mice were monitored for mortality 
for 21 days.
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dpi. 1 dpi.2 dpi.3 dpi.4 dpi.5 Control
B: Cytolytic activity in NK-depleted mice
■ ■ B 6 . S F V  
kxx*xh B6.Mock 
l------ lNK-dep.SFV
Effectors : Targets
Figure 3.2: NK cell activity in SFV infections. (A) NK-mediated cytotoxicity against 
YAC-1 cells using 6h ?1Cr release assay. (B) NK-mediated cytotoxicity diminished in 
NK-depleted mice tested at day 3 postinfection.
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NK-dep.
♦ — B6
Days post-infection
Figure 3.3: Survival of NK depleted (NK-dep.) (n 8) was compared to that of wt B6 
mice (n 8). Mice were 10-week-old, infected with to 1 pfu/mouse vSFV, and monitored 
for mortality for 21 days.
67
Chapter 3: Immunopathology
100 -
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Days post-infection
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IFN-yR'7' 
— B6
— IFN-y’/'
Figure 3.4: IFN-y increases resistant to vSFV infection. Survival of IFN-y'and IFN- 
yR'7' mice and their respective wt counterparts B6, 129 mice (n 20) was compared 
during vSFV infection. Mice were 10-week-old, infected with 1 pfu/mouse vSFV, and 
monitored for mortality for 21 days.
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4.1 Summary
Previously, perfxgzmAB' '  mice (defective in granule exocytosis), gld and Fas'7' mice 
(defective in Fas.L/Fas-mediated killing), and FasxgzmAB'7' and perf!'xgld mice 
(defective in both pathways) have shown significant resistance to vSFV infection (1 
pfu/mouse) compared with B6 mice. In this chapter, I investigated viral replication in 
different tissues of infected mice and found reduced virus titres in tissues harvested from 
perf''xgld mice. Thus, I investigated the underlying factors restricting viral replication in 
perf''xgld mice, and found naive mice to have a remarkable increase in macrophages, 
with RT-PCR of splenocytes showing increased levels of macrophage activating 
cytokines (IFN-y and TNF-a) in their spleens. Reconstituting Fas'7' mice with 
thioglycolate-activated macrophages resulted in restricted viral replication compared to 
non-reconstituted Fas'7' mice. Therefore, the expanded population of macrophages in perf 
1 xgld mice may play a role in increasing their resistance to vSFV infection.
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4.2 Introduction
The positive-stranded RNA alphavirus, SFV, replicates in muscles following peripheral 
infection leading to high-titre plasma viremia detectable within 24 h (Amor et al., 1996; 
Fazakerley et al., 1993). SFV is neuroinvasive and has been shown to infect endothelial 
cells, causing blood-brain barrier damage (Fazakerley, 2002; Pathak and Webb, 1974; 
Soilu-Hanninen et al., 1994). SFV strains can be classified into vSFV and aSFV (Atkins 
et al., 1999); both are lethal in weanling mice, however, they differ in their lethality in 
adult mice. Infection of adult mice with aSFV is mostly asymptomatic, characterised by 
low virus titres in the brain and demyelination that peaks at 14-21 days post-infection 
(Atkins et al., 1999; Fazakerley et al., 1993). In comparison, vSFV infection is 
characterised by high virus titres in the brain, and rapid and lethal encephalitis. Although 
not a human pathogen, infection in mice with aSFV has been investigated as a model for 
multiple sclerosis and experimental allergic encephalitis (Butt et al., 1996; Fazakerley 
and Webb, 1987a). Such studies have shown lesions of demyelination during aSFV 
infection to be immune-mediated, particularly CD8T cell-dependent in BALB/c and 
CBA/H mice (Fazakerley and Webb, 1987a; Fazakerley and Webb, 1987b; Subak-Sharpe 
et al., 1993), and B cell-mediated in C57BL/6 (B6) mice (Smith-Norowitz et al., 2000). 
Interestingly, cytotoxic T (Tc) cell responses against SFV in mice are limited to particular 
major histocompatibility complex (MHC) class I antigens and not elicited in B6 mice 
(Mullbacher and Blanden, 1978).
In addition to secretion of cytokines, Tc and NK cells can use at least two pathways to 
generate cytotoxic attacks against target cells (Henkart, 1994; Rouvier et al., 1993) ; the 
Fas-mediated pathway requires the interaction of the Fas.L on cytotoxic cells with the Fas 
receptor on target cells (Depraetere and Golstein, 1997; Mullbacher, 2003; Nagata, 
1997), whereas the granule exocytosis pathway of cytotoxicity involves the secretion of 
at least two types of effector molecules, perforin and gzms (Russell and Ley, 2002). Both 
gzmA and gzmB have been shown to be important in controlling viral infections 
(Mullbacher et al., 1999). In chapter 3, I compared the susceptibility of mice deficient in 
one or both cytotoxic pathways of NK and Tc cells to infection with vSFV to that of wt 
B6 mice. I found that a deficiency with Fas and /or perforin pathways of cytotoxicity 
increased survival rates of groups of mice. In addition, I showed that absence of Tc cell 
activity as a result of a deficiency in ß2 microglobulin (ß2M'' mice) did not adversely
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impact on survival rate or MTD. Here, I describe the results of investigating the 
underlying factors associated with the significant reduction of disease in mice deficient in 
Fas- and/or granule exocytosis-mediated cytotoxicity following infection with SFV.
4.3 Material and methods
4.3.1 Viruses and cells
Vero and BHK cells were maintained in EMEM plus nonessential amino acids and 5% 
FCS and grown at 37° C in humidified condition with 5% CO2.
Working stocks for vSFV and aSFV were prepared by infecting semi-confluent BHK cell 
monolayers at a multiplicity of 0.5 pfu/cell. Infected cells were incubated for 24 h, 
culture supernatants harvested, centrifuged at 1200 x g for 4 min to remove cell debris, 
and stored in single-use aliquots at -70° C. Virus titres were determined by plaque assay 
on Vero cells and ranged from 5 x 107 pfu/ml for vSFV to 1 x 108 pfu/ml for aSFV.
4.3.2 Animals
B6 mice, syngeneic mice deficient in granzymes A and B plus perforin (perfxgzmAB7) 
(Mullbacher et al., 1999), and syngeneic mice deficient in the Fas-mediated cytolytic 
pathway involving either a loss-of-function mutation in the Fas ligand (gld) (Takahashi et 
ah, 1994), or Fas receptor gene knockout (Fas'7') (Adachi et ah, 1995) were used. Mice 
deficient in both pathways of cytotoxicity were either Fas and gzm A and B negative 
(FasxgzmAB'7') (Rode M, 2004). or deficient in perforin and Fas.L (perf''xgld). Perf7' 
xgld mice were generated by cross-breeding mice heterozygous for perforin and 
homozygous for the Fas.L mutant as previously described (Licon Luna et ah, 2002). 
Throughout this study, 10-week-old female mice were used.
Mice were bred under specific pathogen-free conditions and supplied by the Animal 
Breeding Facilities at the John Curtin School of Medical Research, Canberra.
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4.3.3 Plaque assay
Virus was titrated by plaque formation on semi-confluent monolayers of Vero cells as 
previously described (Licon Luna et al., 2002). Briefly, samples were serially diluted on 
ice in HBSS, pH 7.6, containing 0.2% BSA, and cells inoculated in duplicate with 0.1 ml 
aliquots of the diluted samples. Adsorption was for 1 h at 37°C followed by the addition 
of an agar overlay medium. After 48 h incubation at 37°C, cells were fixed with 5% 
paraformaldehyde (BDH chemicals, Aust.) for 1 h. Over-layers were removed, and fixed 
cells were stained with 0.2% crystal violet in ddHiO. The stain was aspirated and plaques 
counted.
For virus determination in infected mouse tissues, animals were sacrificed at a given time 
post-infection, tissues were aseptically removed, snap-frozen in liquid nitrogen or dry ice, 
and stored at -70°C. 10% (weight/volume) tissue suspensions in ice-cold HBSS (pH 7.6) 
containing 0.2% BSA were homogenized, clarified by centrifugation (18,000 x g for 5 
min at 4°C), and supernatants were stored in aliquots at -70°C. The limit of virus 
detection by plaque assay in tissues and serum samples of infected mice was 10 pfu/g or 
ml, respectively. As a control, brain, spleen, and muscle tissues from uninfected animals 
were homogenised in the presence of a known amount of virus. Plaque titration indicated 
no loss of viral infectivity due to tissue components released during homogenisation.
4.3.4 Flow-Cytometric Analysis
Spleens from uninfected B6, perfxgzmAB 7', gld, Fas’7', FasxgzmAB'7', and perf7’xg/r/ 
mice were harvested and single cell suspensions prepared. After red cell lysis, 
splenocytes were suspended in PBS + 1% FCS at 107 cell/ml. Splenocyte constitutions 
were tested for the percentages of T, B, NK, and macrophage cells using anti-CD3 
allophycocyanin (apc)-conjugated, anti-CD4 fluorescein isothiocyanate (FITC)- 
conjugated, anti-CD8 FITC-conjugated, anti-B220 FITC-conjugated, anti-NKl.l FITC- 
conjugated, and anti-F4/80 FITC-conjugated antibodies (PharMingen). 1 x 106 cells were 
stained with 5 pi of a 1/10 dilution of antibody stocks in PBS. Cells were incubated for 
30 min, washed, and analysed by FACS. Dead cells were labelled by the addition of 5 pi 
of 7-aminoactinomycin D (7AAD) (20 pg/ml) (Sigma). Fc receptors were blocked by the 
addition of 5 pi of a 1/10 dilution of anti-mouse CD16/CD32 (Fey III/II receptor)
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(PharMingen). This antibody and the 7AAD were added prior to the addition of cell 
marker-specific antibodies.
4.3.5 Extraction of RNA, reverse transcription, DNA amplification and 
visualization
Total RNA was extracted from spleens of uninfected mice using TRIzol (Invitrogen) in 
accordance with the manufacturer’s instructions. Reverse transcription using 1 pg total 
RNA was with 200 U Molony murine leukemia virus reverse transcriptase (M-MLV RT) 
(Promega) in the presence of 2.5 mM dNTPs (Astral Scientific), 20 U RNase inhibitor 
(Invitrogen), 1 pg/reaction of random primers, 50 mM Tris-HCl (pH8.8), 75 mM KC1, 3 
mM MgCh, and 10 mM dithiothreitol (DTT) in a volume of 25 pi. Reverse transcription 
was carried out for 1 h at 37°C followed by heating at 94°C for 5 min to inactivate the 
transcriptase. The resulting cDNA was diluted with DNase- and RNase-free water 
(Sigma-Aldrich) to a final volume of 200 pi.
PCR was performed for the housekeeping gene, glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH), IFN-y, and TNF-a (Yoshida et al 2000). Amplification of 5 pi 
of cDNA was achieved using 25pi reaction that contains 0.5 U of Taq polymerase 
(ABgene), magnesium-free buffer [75 mM Tris, 40 mM (NFFThSCU, 0.1% (v/v)Tween 
20] (lOx reaction buffer; ABgene), 2 mM MgCL2 (ABgene) and 2.5 mM dNTPs. The 
reaction mix was incubated at 94°C for 1 min. The reaction was cycled 3 Ox at 94°C for 
30 sec, 55°C for 30 sec, and 72°C for 1 min using Thermocycler (Biorad). These 
reactions were carried in the presence of 5 pmol of sense and anti-sense primers using the 
following primers:
GAPDH sense (5’-GGTGAAGGTCGGTGTGAACGGA-3’)
antisense (5’-TGTTAGTGGGGTCTCGCTCCTG-3’)
IFN-7 sense (5’-CCTCATGGCTGTTTCTGGCTGTTA-3’)
antisense (5’- CATTGAATGCTTGGCGCTGGACC-3’)
TNF-a sense (5’-GAAAGCATGATCCGCGACGTGGA-3’)
antisense (5’-TACGACGTGGGCTACAGGCTTG-3’).
PCR products were electrophoresed on 1.5% agarose gels and stained with ethidium 
bromide. The resultant bands were visualized with an ultraviolet transilluminator and 
compared among B6, perfxgzmAB'7', gld, Fas'7', FasxgzmAB'7', and perf''xgld mice.
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4.3.6 Histology
Midsagittal plane bisected brains were fixed in 10% normal buffered formalin and 
embedded in paraffin. 4 pm sections were stained with hematoxylin and eosin (HE) and 
luxol fast blue (LFB), and tissues were examined for morphology.
4.3.7 Macrophage transfer
10-week-old female Fas'7' mice were injected with thioglycolate (0.03 mg/mouse) 
intraperitoneally (i.p). Four days later, cells were harvested from the peritoneal cavity by 
rinsing 3x with PBS. Cells were washed twice, resuspended in PBS to a final 
concentration of 1 x 10 cell/ml, and 200 pi (2 x 10 cell) were injected i.v into naive Fas' 
7' mice. 2 h after transfer, macrophage-enriched (Fas'7'+M0) and naive Fas’7' mice were 
infected with vSFV (1 pfu/mouse). Tissues were harvested at day 3 and 5 post-infection 
and virus titers were determined by plaque assay.
4.4 Results
4.4.1 Growth of vSFV in tissues of mice defective in Fas- and/or granule 
exocytosis-mediated pathways of cytotoxicity
B6 mice deficient in perforin, gzmA, gzmB, or gzmA&B are marginally more resistant to 
low dose of vSFV infection relative to wt mice. This resistance increases significantly in 
mice lacking functional Fas (Fas'7'), Fas.L (gld), perforin plus gzmA and B (perfxgzmAB' 
7'), or Fas plus gzmA and B (FasxgzmAB'7'). Mice deficient in perforin plus Fas.L (perf7' 
xgld) are most resistant to vSFV infection and represent a third category of SFV 
susceptibility. This is reflected in ~20% mortality, compared to ~70% mortality in wt B6 
mice (chapter 3). These results were interpreted in terms of a deleterious effect of 
cytotoxic Fas- and granule exocytosis-mediated pathways of cytotoxic effector (NK or 
Tc) cells in disease outcome of SFV CNS infection.
Groups of mice (B6, perfxgzmAB'7', gld, Fas'7', FasxgzmAB'7', and perf ''xgld) were 
infected i.v with 1 pfu vSFV, monitored daily, and clinical symptoms recorded. At 2 day 
intervals, mice were sacrificed, serum, spleen, muscle, and brain harvested, and virus 
titres were determined. When the kinetics of SFV replication in extraneural and brain
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tissues of mice defective in granule exocytosis and/or Fas-mediated pathways of 
cytotoxicity were compared to that in B6 wt mice, the pattern of SFV growth in perf7' 
xgld mice differed from that of all other mice strains investigated (figure 4.1). The most 
striking observation was the generally much lower or undetectable presence of SFV in all 
tissues and serum of perf ''xgld mice. Whilst SFV was present in serum of wt, 
perfxgzmAB'7', gld, Fas’7', and FasxgzmAB'7' mice on 2 and 4 days post-infection, with 
titres ranging from 10 -10' pfu/ml, virus was undetectable in perf 'xgld mice. SFV was 
also present in some spleens harvested at 2 and 4 days post-infection from all mouse 
strains other than perf ‘'xgld mice. Given that tissue titres were often not significantly 
higher than the corresponding virus titres in serum, the contribution of virus-containing 
blood to titres in the tissue samples cannot be excluded.
SFV replication in muscle did not yield high virus titres (< 105 pfu/g). SFV was present 
in most mouse strains on all days sampled with the exception of perf7’xg/d mice where it 
was found only on day 8 post-infection. The highest virus titres were obtained in the 
brains of B6 wt and most mutant mice. Again in perf 'xgld mice brain titres of SFV were 
either undetectable or low. In addition, the observed clinical sings associated with vSFV 
infection indicated that the most severe clinical signs such as morbidity and hind limb 
paralysis were mostly correlated to the virus titre in the brains. This was observed in 
groups of B6 wt, perfxgzmAB’7', gld, Fas'7', and FasxgzmAB’7’ mice on day 6 and 8 post­
infection. In contrast, perf7'xg/äf mice did not show clinical signs of morbidity and CNS 
infection.
To confirm the reduced or lack of SFV replication in perf ''xgld mice, groups of B6 wt 
and perf7'xg/<7 mice were infected i.v with 103 pfu of aSFV, brain, spleen, muscle, and 
serum titres were determined at days 2, 4, 6, and 8 post-infection (figure 4.2). Avirulent 
SFV grew to significantly higher titres in spleen on day 2 and 4 post-infection than vSFV, 
reached the CNS but was cleared from the brain between 6 and 8 days post-infection 
without reaching titres > 105 pfu or causing death in B6 wt mice. The low virus titres in 
the brain are a distinct feature of aSFV infection where replication in neurons is restricted 
(Fazakerley et al., 1993) (chapter 2). Replication of aSFV in muscle of B6 wt mice 
resulted in slightly higher titres on day 2 post-infection but presence in this tissue was of 
shorter duration to that of vSFV. The magnitude and duration of viremia did not 
markedly differ between aSFV and vSFV in B6 wt mice (figure 4.2.D and figure 4.1.D).
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A comparison of growth of aSFV in B6 wt and perf7'xg/c/ mice clearly demonstrates 
reduced growth in the double-deficient mouse strain in all tissues tested although viremia 
on day 2 post-infection is comparable.
These results suggest that the absence of clinical symptoms in, and increased survival rate 
of, peri xgld mice during vSFV infection is the result of restrict viral replication rather 
than reduced immune-mediated pathology due to defective cytolytic activity.
4.4.2 Natural antibodies
Mice suffering from generalised lymphoproliferative disease (gld mice) produce large 
amounts of IgG and IgM antibodies (Nagata and Suda, 1995). These antibodies, present 
before viral infection, could play a role in reducing virus growth. To test this possibility, 
serum samples from uninfected gld, perf''xgld, perfxgzmAB'7', and B6 wt mice were 
assessed for their ability to neutralise vSFV in vitro. Serum dilutions were incubated with 
a fixed amount of vSFV at 37°C for 1 h, and neutralizing activity determined by plaque 
assay. No virus neutralizing effect was apparent (Table 4.1). Therefore, any involvement 
for these antibodies in the reduction of virus growth in strains with high serum levels of 
IgG and IgM is unlikely.
4.4.3 Splenocyte subsets
Mice with defect in the Fas pathway develop lymphadenopathy and splenomegaly 
(Cohen and Eisenberg, 1991; Nagata and Suda, 1995). The lymphoproliferative disease 
alters the ratio of NK, macrophages, T, and B cells in spleens which in turn would 
influence the immune response to a viral infection. Table 4.2 shows the cellular 
composition of spleens from B6 wt, perfxgzmAB'7', gld, Fas'7', FasxgzmAB'7', and perf7' 
xgld mice. PerfxgzmAB'7' mice were comparable to B6 wt mice in terms of percentages 
of T (CD3+), B (B220+), NK (NK1.1+) cells, and macrophages (F4/80+) in spleen. The 
percentage of double positive (CD3+B220+) splenocytes was low in wt and perfxgzmAB' 
7' mice. In contrast, an elevated percentage of CD3+B220+ cells, which is characteristic of 
a defect in the Fas pathway, was detected in gld, Fas'7’, FasxgzmAB'7', and perf7'xg/<f 
mice. The percentage of macrophages in spleens of B6, perfxgzmAB'7’, gld, Fas’7’, and 
FasxgzmAB'7' mice was comparable but significantly elevated in perf7'xg/<7 mice, as has
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been previously reported (Spielman et al., 1998). In addition, a slight increased in the 
percentage of NK cells in spleens of perf''xgld mice was observed compared to the other 
mouse strains.
4.4.4 Histology
Perf^xgld mice have been shown previously to suffer from autoimmune diseases. High 
number of activated macrophages have been found in pancreas and ovaries, the later is 
thought to be responsible for female infertility (Spielman et al., 1998). Therefore, I 
investigated whether expanded macrophages in perf ''xgld are responsible for any 
histological differences in their brains compared to B6 wt mice. Abundant monocytes 
were present in the meninges of naive perf ''xgld mice compared to naive B6 mice (figure 
4.3).
4.4.5 RT-PCR analysis for IFN-y and TNF-a expression
High levels of TNF-a and IFN-y in brain of SJL mice were associated with low viral 
titres during SFV infection. In comparison, low levels of TNF-a and IFN-y were 
associated with high viral titres in B6 mice (Mokhtarian et al., 1996). This suggests that 
these cytokine, directly or indirectly, influence SFV replication in mice. Therefore, 
mRNA expression levels for both IFN-y, and TNF-a were studied in naive B6 and 
cytolytic effector function deficient mice. IFN-y mRNA was not detectable in naive B6 
and perfxgzmAB’7" mice but RNA transcripts were clearly present in gld, Fas’/_, and 
FasxgzmAB'7', and elevated levels detected in perf ''xgld mice (figure 4.4). Furthermore, 
in perf ''xgld mice elevated TNF-a mRNA levels were detected in comparison to all other 
strains of mice (figure 4.4).
4.4.6 Transfer of activated macrophages restricts SFV replication in 
vivo
Increased number of activated macrophages in perf ''xgld mice have been implicated in 
immunopathology (Spielman et al., 1998). I investigated the effect of expanded activated 
macrophage populations on viral replication in these mice. My aim was to transfer 
macrophages from perf ''xgld mice into wt B6 strain and then study their effect on viral
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replication. Peritoneal rinsing was used to harvest macrophages; about 4 x 106 cells were 
harvested per perf'’xgld mouse compared to about 1 x 106 cells/B6 mouse. The 
availability of homozygotes perf 'xgld obtained from our breeding program proved to be 
insufficient to permit peritoneal macrophage isolation in sufficient numbers for transfer. I 
therefore used thioglycolate-activated macrophages or transfer.
Fas_/‘ mice were used because of their delayed MTD compared to B6 wt mice (chapter 
3). Macrophage-enriched (Fas'A+M0) and control Fas‘/_ mice were infected with vSFV (1 
pfu/mouse) and tissue titres were determined at day 3 and 5 post-infection. As shown in 
figure 4.5, high virus titres were detected in almost all tissues harvested from control 
mice. This compares with little or no virus detectable in almost all tissues harvested from 
Fas^'&MO mice. These data illustrate the ability of activated macrophages to ameliorate 
SFV infection, and suggest that activated macrophages are at least in part responsible for 
the increased resistance of perf/_xgW mice.
4.4.7 Infection with high dose of vSFV
Death of mice from SFV infection is usually the result of brain damage (Atkins et al., 
1999). If activated macrophages protect perf''xgld mice by preventing viral replication 
and, possibly, brain invasion, such protection would be dependent on the dose of 
infection. To test this, B6 and perf''xgld mice (6 mice per group) were infected i.v with 
103 pfu/mouse vSFV. This dose of infection led to 100% mortality in both perf''xgld and 
B6 mice (figure 4.6). However, perf/_xgld mice showed a delayed MTD (~10 days) 
compared to B6 mice (~7 days). Statistically this delay was significant (P= 0.013, Mann- 
Whitney test). In addition, death in perf ''xgld mice was not associated with hind limb 
paralysis compare to death seen in B6 mice suggesting less neuronal damage in the 
absence of cytolytic activity, and was similar to NK-depleted mice (chapter 3).
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4.5 Discussion
Chapter 3 describes experiments which show that perfxgzmAB'7’, gld, Fas'7', FasxgzmAB' 
7', and perf''xgld mice are significantly more resistant to vSFV infection compared to wt 
B6 mice. Experiments in this chapter were aimed at investigating whether clinical vSFV 
infection differs among these mouse strains. Clinical symptoms such as ruffled fur, 
hunched posture and hind-limb paralysis before death are similar in B6, perfxgzmAB'7', 
gld, Fas"7', and FasxgzmAB’7’ mice. In these strains, the observed seven*symptoms, such 
as paralysis, are clearly associated with high virus titres in the brains. Although a 
cytopathic effect due to SFV per se cannot be excluded, the impaired cytolytic activity of 
mice defective in the Fas or exocytosis mediated pathways of cytolysis and the associated 
reduced damage in the CNS may be responsible for their increased resistance to SFV 
infection. Contrary all other strains, no clinical signs were observed in perf!'xgld 
mice. This is associated with restricted viral replication. Resistance to Flavivirus 
infection with MVE has also been reported in perf''xgld mice (Licon Luna et al., 2002). 
In this instance it was speculated that the increase in resistance was due to lack of 
cytolytic activity of effector T and NK cells and prevention of blood brain barrier 
damage. However, the results shown here suggest that, in perr'xgld  mice, the abundance 
of activated macrophages and the elevated expression levels of IFN-y and TNF-a may 
have limited vSFV infection.
IFN-y induces the expression of MHC-I molecules (Rosa et al., 1986), and MHC-I 
molecules itself have been reported to inhibit Sindbis virus replication (Hahn et al., 
1999). RNA transcripts for IFN-y were detected in naive gld, Fas’7', FasxgzmAB'7', and 
perf7'xg/d mice. Since virus titres in tissues harvested from gld, Fas’7', and FasxgzmAB'7' 
mice were comparable to that of B6 samples, any role for IFN-y in increasing anti-viral 
resistance through induction of MHC-I molecules seems unlikely. Yet, IFN-y must play a 
crucial role in resistance to SFV infection since wt mice of the 129 strain became 
susceptible as a result of IFN-y receptor deficiency (chapter 3). This is supported by 
circumstantial evidence from SJL mice where low SFV titres in brains are associated 
with high levels of TNF-a and IFN-y compared to B6 mice where high SFV titres in the 
brains are associated with low levels of TNF-a and IFN-y (Mokhtarian et al., 1996). IFN- 
y is required for macrophage activation, but must be accompanied by TNF to achieve full
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macrophage activation (reviewed in (Mosser, 2003)). In addition, a synergistic action of 
both IFN-y and TNF-a has been reported to mediate an anti-viral effect in vitro (Wong 
and Goeddel, 1986). Elevated levels of RNA transcripts for both IFN-y and TNF-a 
detected in spleens of naive perf''xgld mice, which is accompanied by the presence of 
activated macrophages in large numbers, may have contributed to resistance in these 
mice.
Although thioglycolate-activated macrophages have the ability to inhibit SFV replication 
in Fas'7' mice, they may have different properties from those found in perf''xgld mice. 
Therefore, confirmation for the role of macrophages in resistance of perf ''xgld mice to 
SFV infection will require further investigations. If activated macrophages play an 
important role in increasing perf/_xgld mouse resistance to SFV infection, their role may 
include an ability to inhibit SFV replication as well as protecting the blood brain barrier. 
Transferring macrophages from perf ''xgld mice into B6 mice could pro^e to be a vital 
experiment illustrating such a role for macrophages in perf ''xgld mice. Since many 
attempts to isolate enough macrophages from perf ''xgld mice for adoptive transfer were 
unsuccessful, macrophage inactivation or depletion studies in these mice may resolve 
these questions.
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Table 4.1. Neutralization assay, natural Abs did not affect infectivity of vSFV in perfA 
xgld.
M ice s tra ins pfu detected  fo r each serum  d ilu tion
1:05 1:10 1:20
B6 8.8x10" 1.1x10" 1.2x10"
9.6x10" 1.2x10" 9.4x10"
perfxgAB';‘ 1.1x10" 1x10" 9.3x10"
1.2x10" 9.6x10" 1.2x10"
gld 8.9x10" 1.1x10" 9.2x10"
lxlO3 9.5x10" 9.4x10"
perf ''xgld 9.2x10" lxlO3 1.1x10"
1.1x10" 8.6x10" 9.2x10"
M o c k 1.2x10" 9x10" 1.1x10"
Neutralisation activity of serum from uninfected B6, perfxgzmAB'7', gld, and perf ''xgld 
mice on vSFV. 2 different serum samples from each strain were tested with no effect 
detected on the infectivity of vSFV. Mock samples represent incubation of virus stock 
alone under similar condition before testing infectivity.
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Table 4 .2 . Lymphocyte constitution showing more macrophages in the spleen of perfA 
xgld mice compared to all other strains.
Cell markers (%±SE)
Strain CD3 B220 CD3+B220 CD4 CD8 NK1.1 F4/80
B6 34.3± 2.2 51.3± 0.7 4± 0.1 22.1 ± 1.1 13.2± 0.1 4 .6± 0.2 7.2± 0.5
perfxgzmAB7' 36.9± 3.9 52.3± 3.3 3. 1± 0.3 22.3± 2.8 13.7± 1.3 4.1 ± 0.1 6.1 ± 0.1
gld 44.2± 3.5 60.6± 2.2 27.9± 2.1 16.9± 0.4 8.6± 0.1 5.3± 0.5 8.5± 1.7
Fas'" 47. 1± 1.8 72.1 ± 0.1 30.2± 5.4 11.6± 0.3 7.4± 0.4 3.9± 0.6 5.9± 0.9
FasxgzmAB 43. 1± 8.7 67.2± 2.6 25.3± 6.6 12.1 ± 1.6 6 .9± 0.2 4 .9± 0.2 7.7± 1.2
perf'xgld 41.6± 5.5 62. 1± 2.5 21. 1± 4.2 13.1 ± 1.2 8.4± 0.9 6 .2± 1.8 17.5± 4.1
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Figure 4.1. Virus titres detected in brain, spleen, muscle, and serum samples at days 2, 4, 
6, and 8 post-infection with vSFV (1 pfu/mouse). While B6, perfxgzmAB7', gld, Fas7', 
and FasxgzmAB7' mice show comparable titres in tested tissues; perf7'xg/J mice show 
restricted viral replication. Virus titres expressed as pfu (logl0)/gm or ml of brain, spleen, 
and muscle or serum, respectively.
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Days post-infection Days post-infection
Figure 4.2. Tissue titres of aSFV are compared between B6 and perf^xgld mice 
following infection with 103 pfu/mouse. Titres detected in tissue samples from perf^xgld 
mice confirm the restricted viral replication previously detected in these mice when vSFV 
where used. Virus titres expressed as pfu (loglO)/gm or ml of brain, spleen, and muscle 
or serum, respectively.
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Figure 4.3. Brains from naive B6 and perf  xgld mice are compared for monocytes 
infiltration. A & B show clear choroid plexus in the brain of B6 mice, whereas C & D 
show monocyte infiltration in the same area in the brain of perf xgld mice.
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Figure 4.4. Elevated mRNA levels of IFN-y and TNF-a in the spleen of naive perf~''xgld 
mice compared to all other strains. GAPDH is a housekeeping gene.
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Figure 4.5. The effect of activated macrophages on SFV replication. Macrophage- 
enhanced and control Fas'/_ mice were infected with vSFV (1 pfu), and tissue titres were 
estimated at day 3 and 5 post-infection. Virus titres expressed as pfu (loglO)/gm or ml of 
brain, spleen, and muscle or serum, respectively.
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perf 'xgld
Days post-infection
/  2  , ,Figure 4.6: Survival of B6 and perf 'xgld mice to vSFV (10 pfu) infection were 
compared.
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5.1 Summary
In this chapter, profiles of cell surface lymphocyte activation markers for both CD3+T 
cells and B (B220+) cells, after infection with different doses of vSFV and aSFV, was 
investigated. The data indicate that the cell surface expression levels of the activation 
markers, CD69 and CD86, were dependent on virus dose and virulence. High dose of 
avirulent and low dose of virulent SFV resulted in more than 80% of T and B cells 
expressMictivation markers within 24 h. These decline to base levels over the next 4 
days. This pattern of cell surface marker expression appears to be a general 
phenomenon in response to viral infections and is not restricted to SFV. The very early 
“activation” of such a high percentage of lymphocytes is mediated by cytokines, 
particularly IFN-I. Inactivated virus does not produce a similar pattern of activation 
marker expression. No increase in CD25 expression was detected following viral 
infection. However, when lymphocytes were treated with mitogens in vitro, CD25 
expression level was elevated.
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5.2 Introduction
Interferons were discovered on the basis of their antiviral activity (Isaacs and 
Lindenmann, 1957). Two types of IFNs can be distinguished: IFN-I and IFN-II (Muller 
et ah, 1994). IFN-II (IFN-y) is structurally unrelated to IFN-I, encoded by a single gene 
(Gray and Goeddel, 1982), and secreted by NK and T cells exclusively (Battistini et al., 
1990; Foster, 1997). IFN-y is primarily involved in immunoregulation (Boehm et al., 
1997). On the other hand, IFN-I (IFN-a, IFN-ß) are encoded by a family of over 20 
genes, (Muller et al., 1994) and can be secreted by a large spectrum of cell types 
(Battistini et al., 1990; Foster, 1997). All IFN-I subtypes bind to a common cell surface 
receptor (Darnell, 1997; Darnell et al., 1994), and play an important role in host 
protection following infection by a variety of viruses (Lobigs et al., 2003; Muller et al., 
1994; Ryman et al., 2000).
Virus-infected cells synthesise IFN-I within hours of infection, and can act in an 
autocrine and paracrine manner to limit replication and spread of virus (Deonarain et 
al., 2000). In addition to their antiviral properties, IFN-I exerts regulatory effects on 
cellular and humoral immune responses. IFN-I stimulates T helper functions in both 
mouse (Evans and Ozer, 1987) and human (Brinkmann et al., 1993), can directly 
support survival of activated T cells (Marrack et al., 1999; Tough et al., 1996), and 
induces bystander cytotoxic T cell proliferation during viral infections, particularly 
memory-T cells (Tough et al., 1996). Moreover, IFN-I stimulates antibody production 
in vitro (Le Bon et al., 2001; Rodriguez et al., 1983), and can act as an adjuvant for 
vaccination against influenza virus (Proietti et al., 2002). However, the role of IFN-I in 
immunoregulation during viral infection in vivo has received little attention.
Lymphocyte activation can be measured by the expression of several cell surface 
molecules such as CD69, CD86, and CD25. CD69 is the first cell surface antigen 
expressed, following activation, on T, B, NK cells, monocytes, and most other 
hematopoietic lineages (reviewed in (Ziegler et al., 1994). CD80 and CD86 are cell 
surface molecules that provide co-stimulation for T cell activation by interaction with 
CD28 (Hakamada-Taguchi et al., 1998), and both molecules can be expressed on 
various APCs such as DCs, macrophages, and B cells (Hathcock et al., 1994). CD25 is 
the a chain of the IL-2 receptor, and can be expressed on the surface of activated B and
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T cells following Ag recognition (Lowenthal et al., 1985). In vitro treatment of B cells 
with IFN-I upregulates the expression of CD69, CD86, and CD25 (Braun et al., 2002).
In this chapter, I investigate the magnitude and kinetics of lymphocyte activation 
associated with an acute cytopathic viral infection in mice. I found that more than 80% 
of splenocytes become activated one day post-infection with splenocyte activation 
markers expression returning to background levels by day 5 post-infection. This 
massive level of lymphocyte activation was a general phenomenon associated with viral 
infections, and mediated by IFN-I.
5.3 Materials and methods
5.3.1 Viruses and cells
Vero and BHK cells were maintained in EMEM plus nonessential amino acids and 5% 
FCS, and incubated at 37° C in humidified condition with 5% CO2.
Working stocks for vSFV and aSFV were prepared by infecting semi-confluent BHK 
cells monolayers at a multiplicity of infection of 0.5 pfu/cell. Infected cells were 
incubated for 24h, culture supernatants harvested, centrifuged at 1200x g for 4 minutes
7
to remove cell debris, and stored in single-use aliquots at -70° C. Titres were 5x 10 
pfu/ml for vSFV and lx 108 pfu/ml for aSFV- based on plaque-titration on Vero cells. 
Stocks of Adenovirus (Ad-2) (Hayder and Mullbacher, 1996) and WNV (Wang et al., 
2003) were prepared as described.
Inactivated preparations of vSFV and aSFV were obtained by y-irradiation (1.3 GRad) 
using a Cobalt-60 source (CSIRO-Canberra). Loss of inactivity of virus replication was 
confirmed by plaque assay.
5.3.2 Mice
Wild type, C57BL/6 (B6) and 129-2SV mice were used in addition to 129 syngeneic 
mice deficient in IFN receptors: IFN-a-receptor knockout (IFN-IR*/_) (Muller et al., 
1994), IFN-y-receptor knockout (IFN-IIR'7') (Huang et al., 1993), and double receptors
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knockout (IFN-I&IIR'7'). Mice were bred under specific pathogen-free conditions and 
supplied by the Animal Breeding Facilities at the John Curtin School of Medical 
Research, Canberra. Only females 10 wk of age were used through out.
5.3.4 Flow-Cytometric Analysis
Spleens from infected and control mice were harvested and single cell suspensions 
prepared. RBC lysis buffer (Ph 7.2), consists of 90% 0.16M NH4C1 and 10% 0.17M 
Tris-base (Ph 7.65), was used to lysis red cells. Splenocytes were incubated in RBC 
lysis buffer (1 ml/spleen) for 3 minute at room temperature. Following incubation, 
splenocytes were washed twice in PBS+1%FCS and resuspended at 1 x 107 cell/ml. 
Lymphocyte subpopulations were estimated using fluorescent-conjugated CD3, CD4, 
CD8 and B220 antibodies (PharMingen). Activation status was assessed using CD69 
(for T and B cells) and CD86 (for B cells) antibodies (PharMingen). lx l06 celbwere 
stained with 5pl of 1/10 antibody dilution in PBS. Cells were incubated for 30 minutes, 
washed, and analysed by FACS. Dead cells were labelled with 7AAD (Sigma), using 
5pl of 1/100 dilution per sample (final concentration is lpg/ml). Fc receptors were 
blocked by the addition of mouse CD16/CD32 (Fey III/II receptor) antibody 
(PharMingen). This antibody and 7AAD were added prior to the addition of cell 
subpopulation and activation marker specific antibodies.
5.4 Results
5.4.1 Activation markers
Cell surface expression of CD69, CD25, and CD86 has been used as an indication of 
lymphocyte activation in vitro (Braun et al., 2002). To evaluate the in vivo activation 
status of splenocytes, B6 mice were infected with aSFV (10 pfu/mouse) and 
expression levels of the markers were determined 1 day postinfection by FACS. As 
shown in figure 5.1, CD69 and CD86 expressions are elevated on both B220+B and 
CD3+T cells. Both CD4+ and CD8+ T cell subpopulations showed a CD69 profile 
similar to that seen on CD3+ cells. Thus, CD3+T cells were used throughout this study 
representing both CD4+T and CD8+T cells. As background levels of CD86 were higher 
on CD3+T cells than on B220+ B cells, CD86 will only be used as an indicator for
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activation of B cells. No increase of CD25 expression was observed on any leukocyte 
cell type. This contrasts with observations from in vitro studies (Braun et al., 2002). 
However, when splenocytes from naive mice were treated in vitro with B (LPS) or T 
(ConA) cell mitogens CD25 expression was induced on the surface of B220+ cells by 
LPS (figure 5.3.A) and on CD3+ cells by ConA treatment (figure 5.3.B).
5.4.2 Lymphocyte activation during SFV infection
Groups of B6 mice were infected with either 1 or 103 pfu vSFV or 1, 103, orlO7 pfu 
aSFV i.v. The percentages of B and CD3+ cells with elevated expression of lymphocyte 
activation markers CD69 and CD86 as shown in Fig 5.2 were measured over a 5 day 
period (Fig 5.4). Kinetics and expression levels of CD69 on B and T cells as well as 
CD86 on B cells were very similar. 1 pfu of aSFV did not result in significant up- 
regulation of lymphocyte activation markers. On the other hand, the same dose of vSFV 
induced expression of activation markers on both B and T cells with peak numbers at 
day 3 post-infection and returning to background levels by day 5 post-infection. 
Increasing the doses of either SFV strain increased the number of lymphocytes with 
activation markers and accelerated their appearance. Infection with inactivated SFV did 
not result in generalized lymphocyte activation (Fig 5.4.Q)-
5.4.3 Systemic feature of lymphocyte activation
To investigate whether lymphocyte activation during SFV infection was systemic or
n
restricted to the spleen, B6 mice were infected with 10 pfu aSFV and activation 
markers on lymphocytes from spleen (figure 5.5.A), lymph node (figure 5.5.B), and 
blood (figure 5.5.C) were determined at day 1 post-infection. Expression of CD69 was 
induced on both B and T cells to similar levels on cells from all tissues tested. CD86 
expression mirrored that of CD69.
5.4.4 General viral infections and lymphocyte activation
To address whether this generalised pattern of lymphocyte activation is a feature of any 
anti-viral immune response, I tested lymphocyte activation using two SFV unrelated 
viruses, Ad-2 a DNA virus and the Flavivirus WNV, a single stranded RNA virus 
similar to SFV. Figure 5.6 shows that i.v infection with either of these two viruses
95
Chapter 5: Activation marker expression
induce similar patterns and magnitude of lymphocyte activation as seen with SFV, 
whereby an elevated expression of CD69 and CD86 was detected on up to 80% of 
splenocytes at day 1 post-infection. This elevated expression of CD69 and CD86 
decreased with time and reached background levels by day 5 post-infection. Thus, 
general lymphocyte activation appears to be an intrinsic property of the hosts’ early 
immune response to viral infections.
5.4.5 Role of IFN-I in lymphocyte activation
The early occurrence of systemic lymphocyte activation after low doses of viral 
infections suggests the possibility that the hosts’ early interferon type-I response may 
be responsible. To test this assumption I compared the magnitude of virus-induced 
lymphocyte activation in mice deficient in type-I and/or type-II interferon receptor(s) 
(IFN-IR'7', IFN-IIR'a, and IFN-I&IIR'7’) with their wt 129 counterpart. Mice were 
infected with 107 pfu aSFV and lymphocyte activation estimated at day 1 postinfection. 
A generalized elevated expression of CD69 on T cells was observed in both wt 129 
(figure 5.7.A) and IFN-IIR'7' (figure 5.7.B) mice. On the other hand, CD69 expression 
on T cells from IFN-IR'7’ (figure 5.7.C) and IFN-I&IIR'7' (figure 5.7.D) mice was 
substantially lower. This dramatically reduced level of expression was also seen for 
CD69 on B cells and CD86 on B cells (figure 5.7) as compared to wt control mice. The 
magnitude of activation marker expression was similar after infection with 10 pfu of 
vSFV or with 107 pfu of aSFV (figure 5.4). Given that vSFV elicits a much stronger 
IFN-I response than aSFV (chapter 2) these results are consistent with the interpretation 
that IFN-I is the predominant mediator for the induction of CD69 and CD86 expression 
on lymphocytes in vivo.
5.5 Discussion
The data described in this chapter demonstrates that in vivo infection with viruses 
causes a generalised activation of lymphocytes as indicated by an elevated expression 
of CD69 and CD86 on both B and T (CD4+ and CD8+) cells. This cell marker 
expression is rapid, virus dose and strain dependent, and appears to be a feature of most 
viral infections (also occurs with poxvirus infection, Müllbacher personal
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communication). Activation marker levels decline to background levels at about 5 days 
post-infection. This observed activation is clearly related to viral replication since 
inactivated SFV did not induce any detectable level of activation at early days post­
infection despite the administration of high doses (5 x 107 pfu equivalent/mouse). This 
also eliminated any possible involvement for FCS and other cellular debris possibly 
present in the viral preparation in the detected lymphocyte activation.
The systemic and generalised activation of tested lymphocytes at very early time 
postinfection suggest the involvement of early released cytokines. Two pieces of 
evidence strongly indicate a major role of IFN-I in this lymphocyte activation. Firstly, 
when IFN-R knockout mice were used, only IFN-IR'7' mice but not IFN-IIR7' mice 
lacked this generalised lymphocyte activation when infected with viruses. These mice, 
in general, are more sensitive and die very early after viral infection (Lobigs et al., 
2003; Muller et al., 1994; Ryman et al., 2000), thus lymphocyte activation were only 
tested at day 1 pi. Secondly, the strength and kinetics of the observed activation marker 
expression correlated with the ability of the individual SFV strain to induce IFN-I. As 
shown in chapter 2, vSFV is a more potent inducer of IFN-I than aSFV. Earlier and 
higher levels of activation marker expression were induced by lower virus doses of 
vSFV compare to aSFV.
IFN-I exerts, in addition to their important antiviral properties, pleiotropic effects 
including inhibition of cell growth, anti-tumour action, involvement in homeostasis, 
and regulatory effects on cellular and humoral responses (reviewed in (De Maeyer and 
De Maeyer-Guignard, 1998). However, the importance of immunoregulation by IFN-I 
during viral infection has not been fully addressed. This is probably because the early 
general concept scientist* tended to believe was that IFNs antiviral effect must be far 
more important than any immunoregulatory role, which if occurs is likely to be local 
(reviewed in (De Maeyer and De Maeyer-Guignard, 1982)). Data presented in this 
chapter illustrate a generalised phenomenon characterised by massive lymphocyte 
activation during early days following viral infection. The biological significant of this 
phenomenon, however, is at present not clear, especially what the host may benefit by 
having 80% of lymphocytes in an activated state, irrespective of their antigen 
specificity. One possibility is that CD69 and CD86 expressions are by products of 
lymphocytes attaining an anti-viral state, which certainly is an advantage to the host
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reducing viral dissemination. In this context the lack of CD25 expression may be 
significant, by not rendering the lymphocytes susceptible to IL-2 mediated 
proliferation. Thus “true activation” may also require CD25 upregulation, which may 
only be triggered by ligation of the clonally expressed antigen receptors.
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g CDS6 exp on B220+B cellsCD69 exp on B220+B cells CD25 exp. on B220+B cells
B7.2 exp. on CD3+T cellsCD25 exp. on CD3+T cellsCD69 exp on CD3+T cells
CD69 exp on CD4+T cells CD69 exp on CD8+T cells
Figure 5.1: CD69 and CD86 expression levels were induced on both B220+B and CD3+T 
cells following in vivo infection with aSFV. CD25 expression level was not induced on 
either cell type. Both CD4+ and CD8+T cells show comparable level of CD69 expression 
to that seen in CD3+T cells.
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A: CD69 (PE) expression on B220+ cells
98.1% 0.0%
B: CD69 (PE) expression on CD3+T cells
0 0%
C: CD86 (PE) expression on B220+ ceils
Mock
9 .0%» 0 0%
f̂l
SFV infected dpi:1
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Figure 5.2: Examples for calculating the percentages of activated B220+B cells and 
CD3+T cells following SFV infection.
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A 2 LPS treated cells (B220+)
Mock
A 1 Con A treated cells (B220+)
.Con A
B 2 LPS treated cells (CD3+)
Mock
B 1 Con A treated cells (CD3+)
Con A
Figure 5.3; CD25 expression after in vitro activation with mitogens Con.A (T cell 
mitogen) or LPS (B cell mitogen). A) CD25 expression on B220+ B cells following 
both Con.A (A.l) and LPS (A.2) treatment. B) CD25 expression on CD3+ T cells 
following both Con.A (B.l) and LPS (B.2) treatment.
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A CD69 expression on B cells
q. 50-
Days post-infection
B: CD69 expression on T cells
Days post-infection
C: CD86 expression on B cell
Q. 50
Days post-infection
100-,
0
0
D: Inactivated aSFV
— B7.2 on B 
-X -C D 69onT  
—O— CD69 on B
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Figure 5.4: Time course of lymphocyte activation as a result of SFV infection. 
Percentage of activated lymphocytes detected at different times after vSFV and aSFV 
infection using different doses. (A) Expression of CD69 on B220+ B cells. (B) 
Expression of CD69 on CD3+ T cells. (C) Expression of CD86 on B220+ B cells. (D) 
Expression of CD69 and CD86 on T and B cells after vaccination with inactivated aSFV.
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Figure 5.5. Lymphocyte activation is systemic during SFV infection. B6 mice infected 
with 107 pfu/mouse aSFV and lymphocytes from spleen (A), lymph nodes (B), and 
blood (C) were tested at day 1 postinfection for CD69 expression on T cell (A.l, B.l, 
and C.l) and B cells (A.2, B.2, and C.2), and CD86 expression on B cells (A.3, B.3, 
and C.3).
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Ac CD69 expresion on B cells B: CD69 expresion on T cells
q. 50-
Days post-infection Days post-infection
C: CD86 expresion on B cells
Days post-infection
Figure 5.6. Percentage of activated lymphocytes after different viral infection, (A) CD69 
expression on B220+ B cells, (B) CD69 expression on CD3+T cells. (C) CD86 expression 
on B220+ B cells.
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7Figure 5.7; Histograms comparing lymphocyte activation in following aSFV (10 
pfu/mouse) infection in wt (129) mice (A), IFN-IIR‘A (B), IFN-IR''' (C), and IFN-I&IIR''’ 
(D) using CD69 expression on T cells (1) and on B cells (2), and CD86 expression on B 
cells (3). In wt mice the activation markers expression levels markedly increased 
following aSFV infection (shaded) compared to mock (open). This detected expression 
was abolished in IFN-IR'7" and IFN-I&IIR'7'. IFN-IIR'' mice show similar activation 
levels to that detected for wt.
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6.1 Summary
The decrease in activated cells was investigated and was found to be not a result of cell 
loss, but rather down-regulation of activation markers. This was associated with the 
inability to display a similar activated phenotype in response to a subsequent viral 
challenge, despite the animal’s susceptibility to the second infection. As these cells 
were responsive to subsequent viral challenge when transferred to a new host, it is 
possible that a refractory period is required to generate a second systemic IFN response 
following an acute viral infection.
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6.2 Introduction
As a result of viral infections, type I IFNs are rapidly induced to provide the first line of 
defence by protecting cells from viral replication and to modulate the immune response 
(Levy and Garcia-Sastre, 2001). Although all virus infected cells can produce IFN-I 
within hours of infection, immature DCs, particularly plasmacytoid dendritic cells 
(pDCs), produce 1000-fold higher IFN-I levels than other cell types, and are 
responsible for a systemic IFN-I responses to many viruses (Le Bon and Tough, 2002). 
Mature DCs are the professional APC to stimulate T cells (reviewed in (Celia et al.,
1997) . These cells are characterised by a decreased level of endocytic activity compared 
to immature DCs (reviewed in (Steinman and Swanson, 1995), with IFN-I playing a 
role in their maturation (Luft et al., 1998; Montoya et al., 2002), probably mediated via 
the induction of IL-15 (Mattei et al., 2001). IFN-I produced by human monocyte- 
derived DCs or murine DCs (derived from spleen or bone marrow) has been shown to 
exert an autocrine stimulatory effect on the respective DC populations (Luft et al.,
1998) . It has been shown that IFN-I induced-during influenza virus infection resulted in 
sustained expression of MHC-I molecules presenting viral peptide by human DCs 
(Celia et al., 1999). In addition, exposure to IFN-I may induce the expression of 
costimulatory molecules such as CD80, and CD86 on DC, which are engaged in 
communication with T cells during activation (Gallucci et al., 1999; Ito et al., 2001; 
Santini et al., 2000). Therefore, IFN-I may serve as a link between innate and adaptive 
immunity through stimulation of both antigen presenting cells and Ag-reactive effector 
cell populations (T and B cells).
In chapter 5, I have described massive generalised lymphocyte activation-marker 
expression during viral infections. This expression was IFN-I-mediated and induced on 
the surface of more than 80% of splenocytes. The percentages of lymphocytes 
expressing activation markers decreased with time to reach background levels at day 5 
postinfection (chapter 5). Attrition of bystander CD8+T cells, particularly of the 
memory phenotype, has been reported during viral infection in response to IFNs 
(McNally et al., 2001). In addition, activated T cells were shown to have reduced 
induction capabilities of IFN-sensitive genes compared to naive cells when both 
populations were subjected to in vitro treatment with IFN-a (Dondi et al., 2003). Thus,
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it was of interest to investigate the fate of activated cells and their responsiveness to 
subsequent viral challenge.
6.3 Material and methods
6.3.1 Viruses and cells
Vero and BHK cells were maintained in EMEM plus nonessential amino acids and 5% 
FCS, and incubated at 37° C in humidified condition with 5% CO2.
Working stocks for vSFV and aSFV were prepared by infecting semi-confluent BHK 
cells monolayers at a multiplicity of infection of 0.5 pfu/cell. Infected cells were 
incubated for 24h, culture supernatants harvested, centrifuged at 1200x g for 4 minutes 
to remove cell debris, and stored in single-use aliquots at -70° C. Titres were 5x 107
o
pfu/ml for vSFV and 1x10 pfu/ml for aSFV- based on plaque-titration on Vero cells. 
Stocks of Ad-2 (Hayder and Mullbacher, 1996) and WNV (Wang et al., 2003) were 
prepared as described.
6.3.2 Mice
Wild type B6 mice were bred under specific pathogen-free conditions and supplied by 
the Animal Breeding Facilities at the John Curtin School of Medical Research, 
Canberra. Only females 10-week-old were used through out.
6.3.3 Flow-Cytometric Analysis
Spleens from infected and control mice were harvested and single cell suspensions 
prepared. RBC lysis buffer (Ph 7.2), consists of 90% 0.16M NH4C1 and 10% 0.17M 
Tris-base (Ph 7.65), was used to lysis red cells. Splenocytes were incubated in RBC 
lysis buffer (1 ml/spleen) for 3 minute at room temperature. Following incubation, 
splenocytes were washed twice in PBS+1%FCS and resuspended at 1 x 107 cell/ml. 
Lymphocyte subpopulations were estimated using fluorescent-conjugated CD3, and 
B220 antibodies (PharMingen). Activation status was assessed using CD69 (for T and
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B cells) and CD86 (for B cells) antibodies (PharMingen). 1 x 106 cells were stained 
with 5pl of 1/10 antibody dilution in PBS. Cells were incubated for 30 minutes, 
washed, and analysed by FACS. Dead cells were labelled with 7AAD (Sigma), using 
5pl of 1/100 dilution per sample (final concentration is lpg/ml). Fc receptors were 
blocked by the addition of mouse CD16/CD32 (Fey III/II receptor) antibody 
(PharMingen). This antibody and 7AAD were added prior to the addition of anti-cell 
markers (CD3, B220, CD69, and CD86) antibodies.
6.3.4 Irradiation, reconstitution, and adoptive transfer
n
Splenocytes at a concentration of 5 x 10 cell/ml in PBS were labelled with the cell 
tracker CFSE at a final concentration of 100 pM. After 5 minutes incubation at room 
temperature, 10 volumes of PBS containing 2% FCS were added and cells were 
centrifuged and washed 3 times with PBS/FCS. CFSE labelled lymphocytes were
Q
resuspended in PBS at a concentration of 2.5 x 10 cell/ml. 10-week-old irradiated (650 
Rad) B6 mice, 24 h after irradiation, were reconstituted with 5 x 107 CFSE-labelled 
cells/mouse. Similarly, 5 x 107 CFSE-labelled cells/mouse were adoptively transferred 
into non-irradiated naive B6 mice.
6.3.5 Lymphocyte responsiveness to a second infection
• * 7Mice were infected with 10 pfu aSFV and splenocytes harvested at day 5 post­
infection. After RBC lysed (described above), splenocytes were labelled with CFSE 
(described above), and 5 x 107 CFSE labelled cells were transferred into naive mice. 2 h
Q
later, mice were infected with Ad-2 virus ( 2 x 1 0  IU/mouse). Activation levels were 
estimated a day later and compared between naive and CFSE labelled cells.
6.5 Results
6.5.1 The fate of activated lymphocytes
The disappearance of activation markers by day 5 post-infection on lymphocytes may 
be the result of two possibilities. One is the loss of activated cells due to activation 
induced cell death (AICD) (Dhein et al., 1995; Ju et al., 1995) and/or attrition caused by
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IFN-I exposure (McNally et ah, 2001), and replenishment by haematopoiesis; the other 
is a reversion of the activation to a quiescent state of the lymphocytes. To differentiate 
between these two possibilities I used sublethally irradiated mice reconstituted with 
CFSE-labelled lymphocytes to monitor their fate after viral infections.
Twenty four hours after sub-lethal irradiation (650 rads), B6 mice were reconstituted 
with CFSE-labelled syngeneic splenocytes and infected with 10 pfu aSFV or mock 
infected and the activation profiles of CFSE-labelled cells were monitored. The CFSE 
profile at day 1 post-infection (day 2 post cell transfer) (figure 6.1.A) and day 5 post­
infection (day 6 post cell transfer) (figure 6.1.C) is similar in both mock and aSFV 
infected mice. CD69 expression on CFSE-labelled splenocytes was markedly elevated 
at day 1 post-infection in aSFV-infected mice (figure 6.1.B), and returned to 
background level by day 5 post-infection (figure 6.1.D).
Some CFSE-labelled splenocytes were shown to have divided following transfer into 
both uninfected and infected recipients (figure 6.1.C). B cells were the least dividing 
cell population both at day 1 and 5 post-infection (figure 6.2.A &B). A portion of 
CD4+T cells underwent at least one division by day 5 postinfection (figure 6.2.C &D). 
CD8+T cells constituted the main dividing splenocyte population with 2 and 4 divisions 
on days 1 (figure 6.2.E) and 5 (figure 6.2.F) post-infection, respectively.
6.5.2 Induction of activation markers after a second unrelated viral 
infection
Sublethally irradiated mice reconstituted with CFSE labelled splenocytes were initially 
infected with aSFV ( 1x10  pfu/mouse). Four days later, these mice were challenged
n
with WNV ( 2x10 pfu/mouse). 24 h after the second infection, CD69 expression was 
tested and compared on splenocytes from mice receiving the initial aSFV infection 
only, and mice subjected to the subsequent infection with WNV. CD69 expression 
levels on splenocytes of mice receiving the subsequent WNV infection did not increase 
above the level detected on splenocytes from mice infected with aSFV (figure 6.1.F). In 
addition, CFSE profiles for splenocytes obtained from mice infected with aSFV alone 
or followed by WNV were similar (figure 6.1 .E). Therefore, 5 days after activation by a
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primary infection, splenocytes are refractory to activation by a subsequent viral 
challenge with an unrelated virus.
6.5.3 Lymphocytes reactivation by secondary viral infection
To assess at what stage previously activated lymphocytes regain their ability to respond 
to a secondary viral infection, and to avoid the proliferation detected for some 
lymphocyte, I adoptively transferred CFSE-labelled splenocytes into B6 mice and 
evaluated their activation pattern after infections with an unrelated virus at different 
time intervals after the primary infection. Twenty four h after transfer, mice were
n %
infected with 1 x 10 pfu/mouse aSFV (primary infection). Either 6 or 9 days later,
o
mice were infected with 2 x 10 IU/mouse Ad-2 virus (subsequent infection). The 
recovery rate and the activation profile of CFSE-labelled cells were assessed 24 h after 
the second infection.
CD69 expression induced by aSFV infection by day 1 post-infection (figure 6.3.A) had 
returned to background levels on day 7 post-infection (figure 6.3.C). At this time point, 
an Ad-2 infection (figure 6.3.D) was unable to induce re-expression of activation 
markers. However, an Ad-2 infection 9 days after the initial aSFV infection induced 
CD69 expression significantly (figure 6.3.F) compared to splenocytes from mice 
infected only with aSFV (figure 6.3.E). The level of CD69 expression induced by the 
Ad-2 infection 9 days after the initial infection with aSFV was comparable to that seen 
in control mice, infected only with Ad-2 (figure 6.3.B). Expression of CD86 was 
similar to that seen for CD69 (figure 6.4). Changing the order of infections, using Ad-2 
as a primary infection and aSFV as a secondary infection, did not change the outcome. 
6 days after the primary Ad-2 infection, mice were infected with aSFV. The secondary 
infection of aSFV failed to induce activation markers expression above levels detected 
for Ad-2 infection alone, which was at background levels (figure 6.5 and figure 6.6).
The numbers of CFSE labelled cells recovered from spleens throughout this experiment 
were monitored to see if activated cells were preferentially lost (i.e undergoing 
apoptosis) compared to non-activated transferred cells. As shown in figure 6.7, the loss 
of CFSE-labelled cells as a result of activation is comparable to that of non-activated 
cells. Generally, there was a decrease in the percentage of CFSE-labelled cells
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recovered from spleens of infected mice at day 7 and 10 post-infection. However, the 
level of reduction was similar in non-infected mice to that of infected mice.
6.5.4 IFN-I mediated antiviral state and lymphocyte activation to 
subsequent infection
To ascertain whether IFNs induced by the initial infection generated an anti-viral state 
responsible for preventing a subsequent infection from becoming established and thus 
preventing renewed IFN-I secretion, Mice were tested to see if they expressed increased
o
resistance to a lethal viral infection. B6 mice were infected with 2x10  iu/mouse Ad-2. 
This dose of Ad-2 virus induces similar level of activation to that of 10 pfu aSFV 
(chapter 5). Ad-2 infected mice were challenged with a lethal dose of vSFV (10J 
pfu/mouse) at day 6 post-infection. Ad-2 infected mice were more susceptible than their 
naive counterpart (figure 6.8). This indicates that the inability of the second viral 
infection to activate lymphocytes was not due to the persistence of a general anti-viral 
state induced by the primary infection, but rather reflects a time requirement for cellular 
signal reprogramming in lymphocytes or regeneration of IFN-secretory capabilities.
6.5.5 Lymphocyte responsiveness to second infection
To investigate whether the refractory period in lymphocytes to undergo a renewed 
activation process is caused by impaired IFN-I synthesis inhibited responsiveness to 
IFN-I of previously activated lymphocytes, mice were infected with 10 pfu aSFV and 
spienocytes were harvested at day 5 post-infection, labelled with CFSE, and transferred 
into naive mice. Two hours later, mice were infected with Ad-2 virus. Expressions of 
activation markers of CFSE-labelled (transferred) and unlabelled (resident) 
lymphocytes were determined 1 day after Ad-2 infection. As shown in figure 6.9, Ad-2 
infection induced cell surface expression of both CD69 and CD86 on both naive and 
CFSE labelled cells. This result proves the ability of previously activated cells to 
respond to renewed viral infection. Thus, it is possible that lymphocyte 
unresponsiveness in the same host is related to the absence of activation factor: IFN-I. 
This needs to be further investigated. The most likely explanation for this detect 
refractory period in activation marker expression is due to exhaustion of IFN-I 
production.
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6.6 Discussion
In chapter 5, I have shown that virus infections in mice lead to a rapid (within 24h) 
expression of activation markers on lymphocytes. Up to 80% of all lymphocytes 
including B, CD4+ and CD8+T cells, in spleen, lymph nodes and blood are affected. 
This generalised lymphocyte activation is primarily mediated by IFN-I. Reversion to 
background levels of activation marker expression occurs at around day 5 post­
infection but does not necessarily coincide with virus clearance. Data obtained by 
adoptive transfer studies using fluorescent labelled splenocytes expressing activation 
markers clearly show that the observed disappearance of activation marker-positive 
cells is not due to cell turnover via apoptosis, but rather that the individual cells 
undergo some sort of a cellular deprogramming of the maturation pathway. Thus, it is 
distinct from AICD, which may be operative only when the maturation pathway is 
initiated via antigen reactive receptor signalling but not when induced by IFN.
Of potential clinical interest is the observation that re-expression of activation markers 
as a result of an infection with a second, unrelated virus does not occur within a 
window of 5-9 days after the primary infection, at a time when activation markers are 
already back to baseline levels. A number of possibilities that may be responsible for 
such a refractory period in activation marker expression have been studied. Firstly, I 
investigated the hypothesis that the anti-viral state induced by the interferon response 
during primary viral infection persisted for an extended time period and thus prevented 
the second viral infection to establish and induce renewed IFN-I release. This, however, 
appears unlikely as mice become less resistant, rather than more resistant to lethal 
vSFV infection when infected during the refractory period induced by an unrelated 
virus. Secondly, I investigated the possibility that the refractory period was due to the 
need of lymphocytes to undergo de-programming to revert to a more naive phenotype 
and that such deprogramming required 7-8 days to be accomplished. However, when 
lymphocytes were taken at the height of the refractory period, transferred into naive 
animals and tracked during viral infection (and consequent high IFN-I-production), 
renewed expression of activation markers was not suppressed. Thus, it reasonable to 
conclude that the refractory period for re-expression of activation markers on 
lymphocytes is due to the failure of the animals to respond to a secondary infection 
with an adequate IFN-I production. It is known that immature DC, particularly pDCs,
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are the principal cell type responsible for the systemic IFN-I release after a viral 
infection (Celia et al., 1999), with IFN-I play a major role in their maturation (Montoya 
et ah, 2002). Thus, it is most likely that the refractory period for re-expression of 
activation markers is due to a lack of DC with capabilities to respond to a new viral 
infection. Infected DC cells may either have been eliminated by the ongoing innate and 
adaptive immune response and not yet replaced, or were undergoing differentiation to a 
non-IFN-I producing phenotype.
The biological significance of this generalized lymphocyte activation is not yet known. 
One can only assume that an early induction of an anti-viral state, especially on 
circulating lymphocytes, would reduce their susceptibility to be infected by the virus 
and thus also reduce dissemination. The consequence of which is an increased 
susceptibility to a secondary infection during the refractory period. In fact, increased 
susceptibility to secondary infections, particularly bacterial infections (reviewed in 
(Beadling and Slifka, 2004)), is a well-known clinical observation and may at least in 
part be due to the phenomena described here.
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A) CFSE dpi: 1
Mock
B) CD69 expresion dpi 1
Mock
D) CD69 expresion dpi5C) CFSE dpi 5
E) CFSE aSFV dpi5 & WNV dpt 1 g F) CD69 exp aSFV dpi 5 & WNV dptl
Mock (thm) 
aSFV (thick) 
WNV (filled)
Figure 6.1. Fate of activated splenocytes. CFSE profiles appeared similar in un­
infected and aSFV infected mice whether tested at dayl post-infection (dpi: 1) (A) and 
day 5 post-infection (dpi:5) (C), and when WNV administered 4 days after the initial 
aSFV infection (E). Expression of CD69 induced on CFSE labelled cells following 
aSFV infection at dpi: 1 (B), and return to background level at dpi:5 (D). 2nd infection 
with WNV did not affect the expression of CD69 (F).
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A) B220+ cells dptl 
R
Mock (thin lme) 
aSFV (solid line)
CFSE
B) B220+ cells dpi 5
F) CD8+ cells dpi:5E) CD8+ cells dpi:l
Figure 6.2. CFSE profiles of different cell types in mock and aSFV infected mice 
following reconstitution. No clear division detected for B cells in both mock and 
infected mice at day 1 post-infection (dpi: 1) (A) and day 5 post-infection (dpi:5) (B), 
very little CD4+T cells divided by day 1 post-infection (C) with very clear one division 
at day 5 (D), 2 division seen for CD8+T cells at day 1 postinfection (dpi: 1) (E) and 
about 4 division at day 5 post-infection (dpi:5) (F).
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Figure 6.3. Fate of activated splenocytes investigated in B6 mice using adoptive 
transfer of CFSE labelled cells. CD69 expression on CFSE labelled cells induced after 
aSFV infection at day 1 post-infection and return to background levels at day 7 post­
infection. CD69 expression was not induced by a secondary Ad-2 infection at day 7, 
but it was induced by day 10. As control, level of CD69 expression induced by Ad-2 
infection at day 1 post-infection tested simultaneously at day 7 and 10.
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Figure 6.4. Fate of activated splenocytes investigated in B6 mice using adoptive 
transfer of CFSE-labelled cells. CD86 expression on CFSE-labelled cells induced after 
aSFV infection at day 1 post-infection and return to background levels at day 7 post­
infection. CD86 expression was not induced by a secondary Ad-2 infection at day 7, 
but it was induced by day 10. As control, level of CD86 expression induced by Ad-2 
infection at day 1 post-infection tested simultaneously at day 7 and 10.
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Figure 6.5. Fate of activated splenocytes investigated in B6 mice using adoptive 
transfer of CFSE labelled cells. CD69 expression on CFSE labelled cells induced after 
Ad-2 infection at day 1 post-infection and return to background levels at day 7 post­
infection. CD69 expression was not induced by a secondary aSFV infection at day 7, 
despite the ability of aSFV to induce CD69 expression in naive mice, tested 
simultaneously.
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CDS6 exp. (Ad (day 1))
Mock (line)
Ad (day lXshaded)
M CD86 exp. (Ad (day 7))
Figure 6.6. Fate of activated splenocytes investigated in B6 mice using adoptive 
transfer of CFSE labelled cells. CD86 expression on CFSE labelled cells induced after 
Ad-2 infection at day 1 post-infection and return to background levels at day 7 post- 
infection. CD86 expression was not induced by a secondary aSFV infection at day 7, 
despite the ability of aSFV to induce CD86 expression in naive mice, tested 
simultaneously.
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Ad Dpi 1 (Recon day 7)
Mock Dpi 1 SFV Dpi 1
SFV(Dpi:7) & Ad(Dpi 1)Mock Dpi 7
SFV (Dpi 10) & Ad (Dpi 1)Mock Dpi 10 SFV Dpi 10
Figure 6.7. Fate of activated splenocytes investigated in B6 mice after adoptive 
transfer of CFSE-labelled cells. Similar percentages of CFSE labelled cells were 
detected in mock and infected mice for each tested day indicating no loss of activated 
lymphocytes from circulation.
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1 0 0 -
Days post-infection
Figure 6.8. Ad-2 infected mice challenged 7 days later with vSFV using 103 
pfu/mouse. Survival was monitored and compared with naive mice receiving same dose 
of vSFV. 5 female 10-week-old B6 mice were used per group.
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CD69 exp.
»1 B) CFSE-labelled cells 
CD86 exp.
"To "To-
Figure 6.9. Activation markers expressions were assayed on cell surface of naive and 
aSFV-primed (6 days), CFSE-labelled, cells. Induced expressions of both CD69 and 
CD86 on were detected at day 1 post Ad-2 infection on both CFSE-labelled (A & B) 
and naive (C & D) cells.
124
C h ap te r 7: C onc lu d in g  rem arks
Chapter 7
Concluding remarks
Chapter 7: Concluding remarks
The experiments described in this thesis were aimed to provide a better understanding 
of the innate and adaptive immune responses during viral infections in general, and the 
alphavirus SFV infection in particular. SFV strains are classified as either virulent or 
avirulent. The experiments described in chapter 2 were aimed at comparing infections 
with vSFV and aSFV in adult mice (10-week-old). The clinical symptoms are similar to 
that described in literature for SFV infection in young mice. Infection with vSFV is 
characterised by high virus titre in the brain associated with an early death (MTD about 
7 days). In comparison, aSFV infection is asymptomatic with restricted replication in 
the brain, but aSFV replicates to high titres in spleen which is not seen with vSFV. 
Replication of aSFV in mature neurons is restricted compared to vSFV, and vSFV brain 
titres reach lethal threshold before immune response intervention (Atkins et al., 1999). 
Physiological changes occurring during neuron maturation does contribute to restricting 
aSFV replication in neurons (reviewed in (Fazakerley, 2002)). Different mouse strains 
show varying levels of sensitivity to SFV infection, which was attributed to differing 
induction levels of cytokines, in particular IFN-y and TNF-a (Mokhtarian et al., 1996). 
Therefore, lethality of vSFV and aSFV may be influenced by their differential ability to 
induce cytokines. The ability of vSFV infection, compared to aSFV, to induce high 
levels IFN-a may be responsible for the reduced vSFV replication in spleen. Lethality 
as a result of vSFV infection is mainly due to virus replication in the brain. Secretion of 
IFN-ß, preferentially expressed in the CNS over IFN-a (Sandberg et al., 1994), may be 
protective, whereas IFN-a has marked CNS toxicity (Akwa et al., 1998; McLaurin et 
al., 1995). Thus, lethality during vSFV infection, which results from neurotropism and 
high replication levels in the brain, may be aided by restricted induction of IFN-a. 
Conversely, clearance of aSFV from the brain is unlikely the result of restricted viral 
replication and adaptive immune response but also IFN-ß induction. Therefore, it will
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be necessary to investigate differences in IFN-a and ß induction in the brain following 
vSFV and aSFV to obtain a broader appreciation of the immunobiology induced by the 
two SFV strains.
Previous studies have shown that the aSFV infection-associated demyelination is 
principally mediated by CD8+T cells in CBA/C3H and BALB/c mice (Fazakerley and 
Webb. 1987; Subak-Sharpe et al., 1993), and B cell mediated in B6 mice (Smith- 
Norowitz et al, 2000). Cytotoxic activities of NK and Tc cells are mediated by granule 
exocytosis and Fas-mediated pathways. Mice defective in cytolytic effector molecules, 
at the gene level, show increased resistance to lethal vSFV infection compared to wild 
type B6 mice. Mice defective in Fas-mediated pathway show more resistance than 
those defective in the exocytosis pathway. These data clearly suggest an 
immunopathological aspect of lymphocyte-mediated cytotoxicity in SFV-infected B6 
mice, with Fas-mediated pathway playing a major role. This finding is supported by the 
ability of SFV to infect a wide variety of cells especially neurons and oligodendrocytes 
(Fazakerley, 2002), and the dominant role of Fas-mediated cytotoxicity in neuronal 
apoptosis (Medana et al., 2001). The absence of Tc cell-mediated cytolytic activity in 
32M'a mice has no effect on the outcome of vSFV infection, whereas NK cells 
depletion results in delayed MTD. In ß2M_/’ mice, absence of MHC-I molecules does 
not result in elevated NK-mediated cytolytic activity during other viral infection, such 
as LCMV (Zajac et al., 1995). Since no Tc cell-mediated cytolytic activity is induced 
after alphavirus infection in B6 mice ((Mullbacher and Blanden, 1978) and chapter 3), 
data presented here suggest the involvement of NK cell-mediated cytolytic activity in 
the immunopathology during SFV infection. Non-cytolytic activity of NK cells, 
however, must play an important role in controlling SFV infection, as vSFV infection
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was more lethal in NK cell-depleted mice despite the delayed MTD. IFN-y is a 
possible candidate for the non-cytolytic anti-viral effect since mice with defective IFN- 
y response show increased sensitivity to lethal vSFV infection compared to their wt 
counterparts. These data illustrate the requirement for non-cytolytic anti-viral response 
to control viral infection in tissues where unrepairable damage by cytolytic activity 
increases the severity of infection. Investigating lethality of vSFV in mice with a 
combination of defects in cytolytic effector molecules and IFN-y, such as of Fas'7' 
xgzmAB'7'xIFN-y'7*, could give additional evidence supporting this conclusion. Such 
mice are expected to have delayed MTD with a high death rate in response to vSFV 
infection.
Comparing vSFV lethality in B6 and syngeneic knockout mice show^that perfxgzmAB 
/", gld, Fas'7’, FasxgzmAB'7', and perf!'xgld miceVfcre significantly more resistant than wt 
B6 mice. Tissue virus titres^re comparable in B6, perfxgzmAB'^, gld, Fas'7*, and 
FasxgzmAB'7' mice. Lethality of vSFV infection in these mice is associated with high 
virus titres in the brain. However, when both pathways of cytotoxicity are defective 
such as in perf7'xgW mice, one would expect elevated tissue virus titres. By contrast, 
perf''xgld mice show restricted viral replication. IFN-y and TNF-a have been reported 
to synergise in generating anti-viral activity in vitro (Wong and Goeddel, 1986). In 
addition, early induction of both cytokines was associated with increased resistance of 
SJL mice to SFV infection compared to B6 mice (Mokhtarian et al., 1996). The 
detection of elevated mRNAs levels for both cytokines in naive perf7'xgld mice 
suggests that these cytokines may be implicated in reduced SFV replication but requires 
further investigation at the protein levels. In addition, both IFN-y and TNF-a are 
associated with macrophage activation, and an expanded population of activated
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macrophages has been detected in perf/_xgld mice. Thus, the possible roles of 
macrophages, IFN-y and TNF-a in restricting viral replication in perf^xgld mice need 
to be established. In vivo macrophage inactivation has been previously used to address 
their involvement in autoimmunity (Spielman et al., 1998). A similar approach may be 
appropriate to address the role of an expanded population of activated macrophages in 
restricting viral replication in pefAxg/c/ mice.
Viral infections are known to elicit an early induction of IFN-I synthesis, which result 
in cellular resistant to viral infection, inhibition of viral replication, and impediment of 
viral dissemination (Sen and Ransohoff, 1993) (van den Broek et al., 1995). In addition, 
In vitro treatment of B cells with IFN-I upregulates the expression of CD69, CD86, and 
CD25 (Braun et al., 2002). Experiments described in chapter 5 demonstrate that in vivo 
viral infections cause an elevation of cell surface expression of CD69 and CD86, but 
not CD25, on more than 80% of both B and T cells. This generalised lymphocyte- 
activation markers expression is systemic, a feature of most viral infections, and mainly 
mediated by IFN-I. The increased expression of CD69 and CD86 may be a by-products 
of the anti-viral effects mediated by IFN-I that help decrease viral dissemination. 
CD86, and CD69 function as costimulatory molecules aiding lymphocytes activation. 
Thus, it is possible that by inducing the expression of costimulatory molecules, IFN-I 
may help to reduce the threshold required for lymphocyte activation. Simultaneous 
administering of inactivated virus and an unrelated live virus, and testing the antibody 
response to the inactivated virus may test this possibility. The function of CD25, 
however, is different to that of CD86 and CD69. CD25 is the a chain of the IL-2 
receptor, and can be expressed on the surface of activated B and T cells following Ag 
recognition (Lowenthal et al., 1985). In vivo cytokine microenvironment must be much
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rr\o(e tightly controlled compared to in vitro systems. Induction of CD25 expression can 
increase lymphocytes susceptibility to IL-2 mediated proliferation, which will not be 
beneficial at such massive scale. In this context the lack of CD25 expression may be 
significant, and “true lymphocyte activation” may also require CD25 upregulation, 
which may only be triggered by ligation of the clonally expressed antigen receptors.
Generally, during acute viral infection a high level of activated cellsxletected at very 
early days postinfection peaking at day 1 postinfection and returning to baseline levels 
by day 5 postinfection. As shown in chapter 6, the disappearance of activation marker­
positive cells is not due to cell turnover via apoptosis but rather down-regulation of cell 
surface expression. Re-expression of activation markers as a result of an infection with 
a second, unrelated, virus does not occur within a window of 5-9 days after the primary 
infection. There are a number of possibilities which could be responsible for this 
refractory period required for marker re-expression. Firstly it could be due to a lasting 
anti-viral state by the initial IFN-I, secondly unresponsiveness of lymphocytes, and 
thirdly an impairment of IFN-I induction. The anti-viral state mediated by IFN-I, 
induced by the primary infection, did not protect the animals from a lethal secondary 
viral infection within the refractory period making it unlikely that persistence of anti­
viral state prevents a secondary infection. In addition, lymphocytes are responsive to a 
second IFN exposure when adoptively transferred to a new host. Therefore, it is 
reasonable to conclude that the refractory period for re-expression of activation markers 
on lymphocytes is due to the animal^ failure to respond to a secondary infection with 
an adequate IFN-I production. This conclusion highlights the importance to study 
immature DC, the principal IFN-I producer after a viral infection (Celia et al., 1999), in
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terms of fate, IFN-I secretion capabilities, and replacement following primary acute 
virus infection.
The biological significance of this phenomenon is not yet clear. What is the benefit to 
the host to have the majority of its lymphocytes in a partially activated state irrespective 
of their antigen reactivity remains to be investigated. However, the phenomenon of 
massive lymphocyte activation following acute viral infection accompanied by a 
refractory period may be of potential clinical interest since it can be associated with an 
increased susceptibility to a secondary infection, particularly bacterial infections. One 
example is the striking association between influenza and respiratory syncytial virus 
(RSV) infections and the subsequent increased cases of sepsis (reviewed in (Beadling 
and Slifka, 2004)). Sepsis is mainly due to secondary bacterial infection and can count 
for more than 215000 deaths per year in the USA. In fact, increased susceptibilities to 
Staphylococcal enterotoxin B and LPS have been reported, in mice, at day 7-8 
following influenza or LCMV infection (Nansen et al., 1997; Nguyen and Biron, 1999; 
Zhang et al., 1996). These studies argue that increased expression of TNF, IL-2, and 
IFN-^ is responsible for the increased severity of the bacterial infection. IFN-I enhances 
Thl- type responses by inhibiting the secretion of Th2-type cytokines (IL-4 and IL-5) 
but promoting Thl-type cytokine production (IFNy) in CD4+T cells (Brinkmann et al., 
1993; Demeure et al., 1994). Thus, prophylactic antibiotic treatment during viral 
infection may avert such scenarios.
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